US20030009215A1 - Clad composite stent - Google Patents
Clad composite stent Download PDFInfo
- Publication number
- US20030009215A1 US20030009215A1 US10/175,254 US17525402A US2003009215A1 US 20030009215 A1 US20030009215 A1 US 20030009215A1 US 17525402 A US17525402 A US 17525402A US 2003009215 A1 US2003009215 A1 US 2003009215A1
- Authority
- US
- United States
- Prior art keywords
- core
- case
- weight percent
- elongate
- filaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21C—MANUFACTURE OF METAL SHEETS, WIRE, RODS, TUBES OR PROFILES, OTHERWISE THAN BY ROLLING; AUXILIARY OPERATIONS USED IN CONNECTION WITH METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL
- B21C1/00—Manufacture of metal sheets, metal wire, metal rods, metal tubes by drawing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21F—WORKING OR PROCESSING OF METAL WIRE
- B21F45/00—Wire-working in the manufacture of other particular articles
- B21F45/008—Wire-working in the manufacture of other particular articles of medical instruments, e.g. stents, corneal rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0033—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements made by longitudinally pushing a protrusion into a complementary-shaped recess, e.g. held by friction fit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00029—Cobalt-based alloys, e.g. Co-Cr alloys or Vitallium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/924—Material characteristic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/12—All metal or with adjacent metals
- Y10T428/12493—Composite; i.e., plural, adjacent, spatially distinct metal components [e.g., layers, joint, etc.]
- Y10T428/12771—Transition metal-base component
- Y10T428/12806—Refractory [Group IVB, VB, or VIB] metal-base component
- Y10T428/12819—Group VB metal-base component
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/12—All metal or with adjacent metals
- Y10T428/12493—Composite; i.e., plural, adjacent, spatially distinct metal components [e.g., layers, joint, etc.]
- Y10T428/12771—Transition metal-base component
- Y10T428/12861—Group VIII or IB metal-base component
- Y10T428/12875—Platinum group metal-base component
Definitions
- the present invention relates to body implantable medical devices, and more particularly to stents and other prostheses configured for high radio-opacity as well as favorable mechanical characteristics.
- prostheses typically of lattice work or open frame construction
- intravascular stents for treating stenosis
- prostheses for maintaining openings in the urinary tracts
- biliary prostheses e.g. esophageal stents
- renal stents e.g. vena cava filters to counter thrombosis.
- One particularly well accepted device is a self-expanding mesh stent disclosed in U.S. Pat. No. 4,655,771 (Wallsten).
- the stent is a flexible tubular braided structure formed of helically wound thread elements.
- the thread elements can be constructed of a biocompatible plastic or metal, e.g. certain stainless steels, polypropylene, polyesters and polyurethanes.
- stents and other prostheses can be expandable by plastic deformation, usually by expanding a dilation balloon surrounded by the prosthesis.
- U.S. Pat. No. 4,733,665 discloses an intraluminal graft constructed of stainless steel strands, either woven or welded at their intersections with silver.
- U.S. Pat. No. 4,886,062 (Wiktor) features a balloon expandable stent constructed of stainless steel, a copper alloy, titanium, or gold.
- Fluoroscopy is the prevailing technique for such visualization, and it requires radio-opacity in the materials to be imaged.
- the preferred structural materials for prosthesis construction e.g. stainless steels and cobalt-based alloys, are not highly radiopaque. Consequently, prostheses constructed of these materials do not lend themselves well to fluoroscopic imaging.
- U.S. Pat. No. 4,681,110 discloses a self-expanding blood vessel liner formed of woven plastic strands, radially compressed for delivery within a tube. A metal ring around the tube is radiopaque.
- U.S. Pat. No. 4,830,003 discusses confining a radially self-expanding stent within a delivery tube, and providing radiopaque markers on the delivery tube. This approach facilitates imaging only during deployment and initial placement.
- the stent itself must be radiopaque.
- the Wolff patent suggests that the stent can be formed of platinum or a platinum-iridium alloy for substantially greater radio-opacity. Such stent, however, lacks the required elasticity, and would exhibit poor resistance to fatigue.
- the Wiktor '110 patent teaches the attachment of metal staples to its blood vessel liner, to enhance radioopacity. However, for many applications (e.g. in blood vessels), the stent is so small that such staples either would be too small to provide useful fluoroscopic imaging, or would adversely affect the efficiency and safety of deploying the stent or other prosthesis.
- This Wiktor patent also suggests infusing its plastic strands with a suitable filler, e.g. gold or barium sulfate, to enhance radio-opacity. Wiktor provides no teaching as to how this might be done. Further, given the small size of prostheses intended for blood vessel placement, this technique is unlikely to materially enhance radio-opacity, due to an insufficient amount and density of the gold or barium sulfate.
- a suitable filler e.g. gold or barium sulfate
- Another object is to provide a resilient body insertable composite filament having a high degree of radio-opacity and favorable structural characteristics, even for stents employing relatively small diameter filaments.
- a further object is to provide a process for manufacturing a composite filament consisting essentially of a structural material for imparting desired mechanical characteristics, in combination with a radiopaque material to substantially enhance fluoroscopic imaging of the filament.
- Yet another object is to provide a case composite prosthesis in which a highly radiopaque material and a structural material cooperate to provide mechanical stability and enhanced fluoroscopic imaging, and further are selectively matched for compatibility as to their crystalline structure, coefficients of thermal expansion, and annealing temperatures.
- a process for manufacturing a resilient body insertable composite filament includes the following steps:
- the radiopaque material has a linear attenuation coefficient, at 100 KeV, of at least 25 cm ⁇ 1 .
- the radiopaque material forms the core, and is at least as ductile as the case.
- the outside diameter of the composite filament, before cold-working preferably is at most about six millimeters (about 0.25 inches).
- the cold-working step can include drawing the composite filament serially through several dies, with each die plastically deforming the composite filament to reduce the outside diameter. Whenever a stage including one or more cold-working dies has reduced the cross-sectional area by at least 25%, an annealing step should be performed before any further cold-working.
- the initial outside diameter of the composite structure typically is at least fifty millimeters (about two inches) in diameter. Then, before cold-working, the composite filament is subjected to temperatures in the annealing range while the outside diameter is substantially reduced, either by swaging or by pulltrusion, in successive increments until the outside diameter is at most about 6 millimeters (0.25 inches). The resulting filament is processed as before, in alternative cold-working and annealing stages.
- the composite filament can be severed into a plurality of strands.
- the strands are arranged in two oppositely directed sets of parallel helical windings about a cylindrical form, with the strands intertwined in a braided configuration to form multiple intersections.
- the strands are maintained in a predetermined uniform tension, they are heated to a temperature in the range of about 700-1200° F., more preferably 900-1000° F., for a time sufficient to age harden the helical windings.
- the result of this process is a resilient, body implantable prosthesis.
- the prosthesis has a plurality of resilient strands, helically wound in two oppositely directed sets of spaced apart and parallel strands, interwoven with one another in a braided configuration.
- Each of the strands includes an elongate core and an elongate tubular case surrounding the core.
- a cross-sectional area of the core is at least ten percent of the cross-sectional area of the strand.
- the core is constructed of a first material having a linear attenuation coefficient of at least 25 cm ⁇ 1 at 100 KeV.
- the case is constructed of a resilient second material, less ductile than the first material.
- the process can be employed to form a body compatible device comprising an elongate filament substantially uniform in lateral cross-section over its length and including an elongate cylindrical core and an elongate tubular case surrounding the core.
- One of the core and case is constructed of a first material having a yield strength (0.2% offset) of at least twice that of the second material.
- the other of the core and case is constructed of a second material being radiopaque and at least as ductile as the first material.
- the core is constructed of tantalum for radio-opacity
- the case is constructed of a cobalt-based alloy, e.g. as available under the brand names “Elgiloy”, “Phynox” and “MP35N”.
- the “Elgiloy” and “Thynox” alloys contain cobalt, chromium, nickel, and molybdenum, along with iron. Either of these alloys is well matched with tantalum, in terms of overlapping annealing temperature ranges, coefficients of thermal expansion and crystalline structure.
- the tantalum core and alloy case can be contiguous with one another, with virtually no formation of intermetallics.
- an intermediate layer e.g. of tantalum, niobium, or platinum
- tantalum, niobium, or platinum can be formed between the core and the case to provide a barrier against intermetallic formation.
- a biocompatible coating or film can surround the case. Tantalum, platinum, iridium, titanium and their alloys, or stainless steels can be used for this purpose.
- the composite filaments can be employed in constructing other implantable medical devices, e.g. vena cava filters, blood filters and thrombosis coils.
- vena cava filters e.g. vena cava filters
- blood filters e.g. vena cava filters
- thrombosis coils e.g. vena cava filters
- a resilient, body compatible prosthesis which, despite being sufficiently small for placement within blood vessels and similarly sized body cavities, has sufficient radio-opacity for fluoroscopic imaging based on the prosthesis materials themselves.
- FIG. 1 is a side elevation of a self-expanding stent constructed according to the present invention
- FIG. 2 is an end elevational view of the stent
- FIG. 3 is an enlarged partial view of one of the composite filaments forming the stent
- FIG. 4 is an enlarged sectional view taken along the line 4 - 4 in FIG. 3;
- FIGS. 5 - 9 schematically illustrate a process for manufacturing the stent
- FIG. 10 schematically illustrates a swaging step of an alternative process for manufacturing the stent
- FIG. 11 is an end elevational view of an alternative embodiment filament
- FIG. 12 is an elevational view of several components of an alternative composite filament constructed according to the present invention.
- FIG. 13 is an end elevational view of the composite filament formed by the components shown in FIG. 12.
- FIG. 14 is an end elevational view of another alternative embodiment composite filament.
- Stent 16 is of open mesh or weave construction, consisting of two sets of oppositely directed, parallel and spaced apart helically wound strands or filaments indicated at 18 and 20 , respectively.
- the sets of strands are interwoven in an over and under braided configuration to form multiple intersections, one of which is indicated at 22 .
- Stent 16 is illustrated in its relaxed state, i.e. in the configuration it assumes when subject to no external stresses.
- the filaments or strands of stent 16 are resilient, permitting a radial compression of the stent into a reduced-radius, extended-length configuration suitable for transluminal delivery of the stent to the intended placement site.
- stent 16 can have a diameter of about ten millimeters in the relaxed state, and is elastically compressed to a diameter of about 2 millimeters (0.08 inches) and an axial length of about twice the axial length of the relaxed stent.
- different applications call for different diameters.
- Inelastic open-weave prostheses provide an alternative to resilient prostheses.
- Resilient or self-expanding prostheses often are preferred, as they can be deployed without dilation balloons or other stent expanding means.
- Self-expanding stents can be preselected according to the diameter of the blood vessel or other intended fixation site. While their deployment requires skill in stent positioning, such deployment does not require the additional skill of carefully dilating the balloon to plastically expand the prosthesis to the appropriate diameter.
- the self-expanding stent remains at least slightly elastically compressed after fixation, and thus has a restoring force which facilitates acute fixation.
- a plastically expanded stent must rely on the restoring force of deformed tissue, or on hooks, barbs, or other independent fixation elements.
- materials forming the strands for filaments must be strong and resilient, biocompatible, and resistant to fatigue and corrosion.
- Vascular applications require hemocompatibility as well.
- materials meet these needs including stainless “spring” steels, and certain cobalt-based alloys: more particularly two alloys including cobalt, chromium, iron, nickel and molybdenum sold under the brand names “Elgiloy” (available from Carpenter Technology Corporation of Reading, Pa.) and “Phynox” (available from Metal Imphy of Imphy, France), respectively.
- Another suitable cobalt-chromium alloy is available under the brand name “MP35N” from Carpenter Technology Corporation of Reading, Pa. and Latrobe Steel Company, Latrobe, Pa.
- the filaments can have a diameter of about 0.1 millimeter (0.004 inches), with adjacent parallel filaments spaced apart from one another by about 1-2 millimeters (0.04-0.08 inches) when the stent is in the relaxed state.
- Fluoroecopic imaging of a conventional open weave prosthesis is extremely difficult. Due to their minute diameters and the materials involved, the filaments exhibit a relatively poor contrast to body tissue for fluoroscopic imaging purposes. The filaments also require a high degree of spatial resolution in the imaging equipment involved. Thus, a stent recognizable on X-ray film may not be distinguishable for real time imaging, due to the relatively poor spatial resolution of the video monitor as compared to X-ray film.
- prosthesis 16 is substantially more amenable to fluoroscopic imaging, due to the construction of strands 18 and 20 .
- the strands cooperate to present a sufficiently radiopaque mass at the tangents of device 16 (parallel to the X-rays) for satisfactory real time imaging.
- a filament 18 a of the prosthesis is of composite construction, with a radiopaque core 24 surrounded by and concentric with an annular resilient case 26 .
- Core 24 is highly absorptive of X-rays, preferably having a linear attenuation coefficient of at least 25 (and more preferably at least 40) cm ⁇ 1 at 100 KeV.
- core 24 is preferably a ductile material so that it readily conforms to the shape of the case
- case 26 is formed of a highly resilient material, preferably with a yield strength (0.2% offset) of at least 150,000 psi. More preferably, the yield strength is at least 300,000 psi. Consequently, the mechanical behavior of composite filament 18 a in terms of elastic deformation in response to external stresses is, essentially, the behavior of case 26 .
- core and case materials In addition to individual characteristics of the core and case, it is desirable to selectively match core and case materials based on certain common characteristics.
- the core and case materials should have the same or substantially the same linear coefficients of thermal expansion. Similarity of core and case materials in their crystalline structure is also an advantage.
- the core and case materials should have an overlap in their annealing temperature ranges, to facilitate manufacture of the filaments according to the process to be explained.
- core 24 is formed of tantalum
- case 26 is formed of a cobalt-based alloy, more particularly Elgiloy (brand) alloy.
- Tantalum is a ductile metal having an atomic number of 73 and a density of about 0.6 pounds per cubic inch. Its linear attenuation coefficient, at 100 KeV, is 69.7 cm ⁇ 1 .
- the Elgiloy alloy includes principally cobalt and chromium, and has an effective atomic number of less than thirty and a density substantially less than 0.5 pounds per cubic inch. However, the alloy is body compatible, hemocompatible and highly resilient, with a yield strength (0.2% offset) of at least 350,000 psi, after cold working and age hardening.
- Case 26 and core 24 thus cooperate to provide a prosthesis that can be viewed in vivo, and in real time.
- the amount of core material in relation to the amount of case material must be sufficient to insure radio-opacity while maintaining the favorable mechanical characteristics of stent 16 .
- the area of core 24 taken along a transverse or lateral plane as illustrated in FIG. 4, should be within the range of about ten percent to forty-six percent of the filament lateral cross-sectional area, i.e. the area of the combined case and core.
- Tantalum and the Elgiloy alloy are well matched, in that the materials have similar linear coefficients of thermal expansion (3.6 ⁇ 10 ⁇ 6 per degree F. and 8.4 ⁇ 10 ⁇ 6 per degree F., respectively), similar crystalline structures, and annealing temperatures in the range of 1700-2300° F. Further, there is virtually no tendency for the formation of intermetallic compounds along the tantalum/Elgiloy alloy interface.
- Platinum and platinum alloys also are suitable as materials for core 24 .
- the atomic number of platinum is 78, and its density is 0.775 pounds per cubic inch. Its linear attenuation coefficient at 100 MeV is 105 cm ⁇ 1 .
- the linear coefficient of thermal expansion for platinum is about 4.9 ⁇ 10 ⁇ 6 per degree F.
- platinum is structurally more compatible with the Elgiloy alloy, and more effectively absorbs X-rays. Accordingly, platinum is particularly well suited for use in prostheses formed of small diameter filaments.
- radiopaque core 24 includes gold, tungsten, iridium, rhenium, ruthenium, and depleted uranium.
- Other materials suitable for case 26 include other cobalt-based alloys, e.g. the Phynox and MP35N brand alloys. Cobalt-chromium and cobalt-chromium-molybdenum orthopedic type alloys also can be employed, as well as alloys of titanium-aluminum-vanadium.
- the MP35N alloy is widely available, and has a potential for better fatigue strength due to improved manufacturing techniques, particularly as to the vacuum melting process.
- the titanium-aluminum-vanadium alloys are highly biocompatible, and have more moderate stress/strain responses, i.e. lower elastic moduli.
- Composite filaments such as filament 18 a are manufactured by a drawn filled tubing (DFT) process illustrated schematically in FIGS. 7 - 9 .
- the DFT process can be performed, for example, by Fort Wayne Metals Research Products corporation of Ft. Wayne, Ind.
- the process begins with insertion of a solid cylinder or wire 28 of the core material into a central opening 30 of a tube 32 of the case material.
- Core wire 28 and tubing 32 are substantially uniform in transverse or lateral sections, i.e. sections taken perpendicular to the longitudinal or axial dimension.
- tube 32 can have an outer diameter d. of about 0.102 inch (2.6 mm) and an inner diameter d2 (diameter of opening 30 ) of about 0.056 inches (1.42 mm).
- Core or wire 28 has an outer diameter d3 slightly less than the tube inner diameter, e.g. 0.046 inches (1.17 mm).
- the wire outer diameter is sufficiently close to the tubing inner diameter to insure that core or wire 28 , upon being inserted into opening 30 , is substantially radially centered within the tubing.
- the interior tubing diameter must exceed the core outside diameter sufficiently to facilitate insertion of the wire into an extended length of wire and tubing, e.g. at least twenty feet.
- tubing inner diameter and the core outer diameter vary with the materials involved.
- platinum as compared to tantalum has a smoother exterior finish when formed into the elongate wire or core.
- the outer diameter of a platinum wire can more closely approximate the inner diameter of the tube.
- the optimum diameter values vary with the materials involved, and the expected length of the composite filament.
- composite filament 34 is drawn through three dies, indicated at 36 , 38 , and 40 , respectively.
- composite filament 34 is cold-worked in radial compression, causing the case tube 32 and the tantalum core wire 28 to cold flow in a manner that elongates the filament while reducing its diameter.
- case tube 32 is elongated and radially reduced to a greater extent than core wire 28 , due to the minute radial gap that allowed the insertion of the core into the tube.
- the radial gap is closed rapidly as the filament is drawn through die 36 , with subsequent pressure within die 36 and the remaining dies cold-working both the core and case together as if they were a single, solid filament.
- the cold-working within all dies forms a pressure weld along the entire interface of the core and case, to form a bond between the core and case material.
- each die the cold-working induces strain hardening and other stresses within the filament.
- respective heating stage is provided, i.e. furnace 42 .
- composite filament 34 is heated to a temperature in the range of from about 1700 to about 2300° F., or more preferably 1950-2150° F.
- substantially all of the induced stresses are removed from the case and core, to permit further cold-working.
- Each annealing step is accomplished in a brief time, e.g. in as few as one to fifteen seconds at annealing temperature, depending on the size of composite filament 34 .
- FIG. 6 illustrates one cold-working stage and annealing stage
- the appropriate number of stages is selected in accordance with the final filament size, the desired degree of cross-sectional area reduction during the final cold-working stage, and the initial filament size prior to cold-working.
- a reduction of lateral cross-sectional area in the range of about forty percent to eighty percent is preferred, and a range of about fifty-five percent to sixty-five percent is highly preferred.
- the successive cold-working and annealing steps give rise to the need for matching the core and case materials, particularly as to their coefficients of thermal expansion, elastic, moduli in tension, annealing temperature ranges, total elongation capacities, and also as to their crystalline structure.
- a good match of elastic moduli, elongation, and thermal expansion coefficients minimizes the tendency for any ruptures or discontinuities along the core/case interface as the composite filament is processed.
- Crystalline structures should be considered in matching core and case materials.
- the Elgiloy alloy, and other materials used to form case tube 32 commonly experience a transformation between the cold-working and aging steps, from a face centered cubic crystalline structure to a hexagonal close packed crystalline structure.
- the Elgiloy alloy experiences shrinkage as it undergoes this transformation. Accordingly, the core material must either experience a similar reduction, or be sufficiently ductile to accommodate reduction of the case.
- composite filament 34 is formed into the shape intended for the device incorporating the filament.
- several filaments or strands 34 a - e are helically wound about a cylindrical form 48 and held in place at their opposite ends by sets of bobbins 50 a - e and 52 a - e .
- Strands 34 a - e can be individually processed, or individual segments of a single annealed and cold-worked composite filament, cut after the final cold-working stage. In either event, the filaments cooperate to form one of the two oppositely directed sets of spaced apart and parallel filaments that form a device such as stent 16 . While only one set of filaments is shown, it is to be understood that a corresponding group of filaments, helically wound and intertwined about form 48 in the opposite direction, are supported by corresponding bobbins at the opposite filament ends.
- a useful prosthesis depends, in part, upon correctly supporting the filaments.
- the filaments are maintained in tension, and it is important to select the appropriate tensile force and apply the tensile force uniformly to all filaments. Insufficient tensile force may allow wire cast or lift effects to cause the individual filaments to depart from their helical configuration when released from the bobbins, and the braided structure of the stent may unravel.
- FIG. 9 illustrates two filaments 34 a and 54 a , one from each of the oppositely wound filament sets, supported by respective bobbins 50 a / 52 a and 56 a / 58 a in a furnace 60 for age hardening in a vacuum or protective atmosphere.
- Age hardening is accomplished at temperatures substantially lower than annealing, e.g. in the range of about 700-1200° F., more preferably 900-1022° F.
- the filaments overly one another to form several intersections, one of which is indicated at 62 . When the filaments are properly tensioned, slight impressions are formed in the overlying filament at each intersection. These impressions, or saddles, tend to positionally lock the filaments relative to one another at the intersections, maintaining the prosthesis configuration without the need for welding or other bonding of filaments at their intersections.
- the age hardening stage is performed after the winding and tensioning of all filaments, i.e. both oppositely directed sets. Accordingly, during age hardening, the filaments are locked relative to one another at multiple intersections. The preferred time for age hardening is about 1-5 hours.
- This age hardening step is critical to forming a satisfactory self-expanding prosthesis, as it substantially enhances elasticity, yield strength, and tensile strength. Typically, the elastic modulus is increased by at least 10% and the yield strength (0.2% offset) and tensile strength are each increased by at least 20%.
- a substantially larger and shorter composite filament 64 (e.g. six inches long with a diameter of approximately ten cm) can be subjected to a series of elongation/diameter reduction steps.
- FIG. 10 schematically illustrates two swaging dies 66 and 68 , which may be used in the course of a hot working billet reduction process.
- the diameter reduction can be accomplished by extrusion/pulltrusion at each stage.
- the composite structure or filament can be further processed by drawing it through dies and annealing, as illustrated in FIG. 6 for the previously discussed process. As before, the composite filament is ready for selective shaping and age hardening after the final cold-working stage.
- the swaging or pulltrusion approach involves substantially increased hot and cold-working of the composite structure or filament, and the initial assembling of the core into the case or shell tubing is easier.
- the structure is subjected to annealing temperatures for a substantially longer time, e.g. half an hour to an hour, as opposed to the one to fifteen second anneal times associated with the process depicted in FIG. 6. Consequently, particular care must be taken to avoid combinations of core and case materials with tendencies for intermetallic formation along the core/case interface. Further, the required hot working of the larger billet may not afford the same degree of metallurgical grain refinement.
- the preferred composite filaments have: (1) sufficient radio-opacity to permit in vivo viewing; (2) the preferred mechanical properties; and (3) a sufficiently low cost.
- the interrelationship of these factors requires that all three be taken into account in determining filament size, relationship of core 24 to case 26 as to size, and materials selected for the core and case.
- core 24 should be at least about 0.0015 inches in diameter, if a stent constructed of such filament is to be visible using conventional radiographic imaging equipment.
- structural requirements particularly elasticity for a self-expanding stent
- the visibility requirement effectively imposes a minimum diameter upon case 26 as well as core 24 .
- appropriate selection of core and casing materials can reduce the required minimum diameters.
- potential substitute materials should be considered in view of their impact on cost—not only the material cost per se, but also as to the impact of such substitution on fabrication costs.
- the core material is tantalum
- the casing is constructed of the Elgiloy brand cobalt-based alloy.
- the maximum outer diameter of the composite filament is about 0.150 mm, or about 0.006 inches.
- Elgiloy filaments of this diameter or larger may be sufficiently radiopaque without a core of tantalum or other more radiopaque material.
- radio-opacity is improved with a tantalum core, and likewise with a core of a tantalum-based alloy, platinum, platinum-based alloy, tungsten, a tungsten-based alloy or combination of these constituents.
- the preferred core size varies with the filament diameter.
- the core should contribute at least about one-third of the cross-sectional area of the composite filament.
- Composite filaments of this structure have core diameters in the range of 0.037-0.05 mm (0.00150-0.002 inches), with filament diameters up to about 0.135 mm or about 0.0055 inches.
- the core is formed of a platinum-10% nickel alloy, i.e. 90% platinum and 10% nickel by weight. While the preferred proportion of nickel is 10%, satisfactory results can be obtained with nickel ranging from about 5% to about 15% of the alloy.
- the case is constructed of the Elgiloy alloy.
- the platinum-nickel alloy as compared to pure tantalum, has superior radiographic and structural properties. More particularly, the alloy has a greater density, combined with a higher atomic number factor (z) for a 10-20% improvement in radio-opacity. Further as compared to tantalum, the alloy is more resistant to fatigue and thus better withstands processes for fabricating stents and other devices.
- a core formed of a platinum-nickel alloy can constitute up to about 40% of the total filament cross-sectional area. Consequently the alloy is particularly well suited for constructing extremely fine filaments.
- This structure of composite filament is suitable for constructing stents having diameters (unstressed) in the range of about 3.5-6 mm.
- a third filament structure involves an Elgiloy case and a core formed of a tantalum-10% tungsten alloy, although the percentage of tungsten can range from about 5% to about 20%.
- the tantalum/tungsten alloy is superior to tantalum in terms of mechanical strength and visibility, and costs less than the platinum-nickel alloy.
- case 26 is formed of the Elgiloy alloy
- core 24 is formed of a platinum-20 to 30% iridium alloy.
- the platinum-iridium alloy can include from about 5 to about 50% iridium.
- the platinum-iridium alloy may exhibit less resistance to fatigue. This is due in part to segregation which may occur during cooling of an alloy containing 30% (by weight) or more iridium, due to the relatively high melting point of iridium. Also, hot working may be required if the alloy contains more than 25% iridium, thereby making final cold reduction of the composite difficult.
- a fifth filament structure employs an Elgiloy alloy case and a core of a platinum-tungsten alloy having tungsten in the range of about 5-15%, and more preferably 8%.
- the radio-opacity of this alloy is superior to the platinum-nickel alloy and it retains the favorable mechanical characteristics.
- casing 26 is constructed of a titanium-based alloy. More particularly, the alloy can be an alloy known as “grade 10” or “Beta 3 ” alloy, containing titanium along with molybdenum at 11.5%, zirconium at 6%, and tin at 4.5%. Alternatively, the titanium-based alloy can include about 13% niobium, and about 13% zirconium.
- Core 24 can be formed of tantalum. More preferably, the core is formed of the platinum-10% nickel alloy. In this event, a barrier of tantalum should be formed between the core and case, as is discussed in connection with FIGS. 12 and 13.
- the titanium-based alloy case is advantageous, particularly to patients exhibiting sensitivity to the nickel in the Elgiloy alloy, and may further be beneficial since it contains neither cobalt nor chrome. Also, because of the lower modulus of elasticity of the titanium-based alloy (as compared to Elgiloy), stents or other devices using the titanium-based alloy exhibit a more moderate elastic response upon release from a deployment catheter or other device. This may tend to reduce vascular neointimal hyperplasia and consequent restenosis.
- the lower elastic modulus results in a less favorable matching of the case and core as to elasticity.
- the proportion of core material to case material must be reduced.
- this construction is suitable for filaments having diameters in the range of about 0.10-0.30 mm.
- core 24 is constructed of a tungsten-based alloy including rhenium at 5-40 weight percent. More preferably, the alloy includes rhenium at about 25 percent by weight.
- Further preferred materials for core 24 include alloys of about 85-95 weight percent platinum and about 5-15 weight percent nickel: alloys including about 50-95 weight percent platinum and about 5-50 weight percent iridium; alloys including at least 80 weight percent tantalum and at most 20 weight percent tungsten; and alloys including at least 60 weight percent tungsten and at most 40 weight percent rhenium.
- Further suitable case materials are alloys including about 30-55 weight percent cobalt, 15-25 weight percent chromium, up to 40 weight percent nickel, 5-15 weight percent molybdenum, up to 5 weight percent manganese, and up to 25 weight percent iron.
- the material should have a yield strength of at least 150,000 psi (0.2% offset). While less preferred, the case material can have a yield strength of at least 100,000 psi (0.2% offset).
- FIG. 11 is an end elevation of a composite filament 74 including a central core 76 of a structural material such as the Elgiloy alloy, surrounded by a radiopaque case 78 , thus reversing the respective functions of the core and case as compared to composite filament 34 .
- Composite filament 74 as compared to filament 34 , presents a larger and less refractive radiopaque profile for a given composite filament diameter.
- Composite filament 74 is more difficult to manufacture than filaments that employ the structural material as the case.
- FIGS. 12 and 13 show a further alternative composite filament 80 , consisting of a central radiopaque core 82 , an outer annular structural case 84 , and an intermediate annular layer 86 between the core and the case.
- Intermediate layer 86 provides a barrier between the core and case, and is particularly useful in composite filaments employing core and case materials that would be incompatible if contiguous, e.g. due to a tendency to form intermetallics.
- Materials suitable for barrier layer 86 include tantalum, niobium and platinum.
- the core, barrier layer and case can be provided as a cylinder and two tubes, inserted into one another for manufacture of the composite filament as explained above.
- FIG. 14 illustrates another alternative embodiment composite filament 88 having a central radiopaque core 90 , a structural case 92 , and a relatively thin annular outer cover layer 94 .
- Composite filament 88 is particularly useful when the selected mechanical structure lacks satisfactory biocompatibility, hemocompatibility, or both.
- Suitable materials for cover layer 94 include tantalum, platinum, iridium, niobium, titanium and stainless steel.
- the composite filament can be manufactured as explained above, beginning with insertion of the radiopaque core into the structural case, and in turn, inserting the case into a tube formed of the cover material.
- cover layer 94 can be applied by a vacuum deposition process, as a thin layer (e.g. from ten to a few hundred microns) is all that is required.
- An elongate tantalum core having a diameter of 0.46 inches (1.17 mm) was assembled into an Elgiloy alloy case having an outer diameter of 0.102 inches (2.6 mm) and an inner diameter of 0.056 inches (1.42 mm). Accordingly, the lateral cross-sectional area of the tantalum core was about 25% of the composite filament lateral cross-sectional area.
- Composite filaments so constructed were subjected to 5-6 alternating stages of cold-working and annealing, to reduce the outer diameters of the composite filaments to values within the range of 0.004-0.0067 inches.
- the tantalum core diameters were reduced to values in the range of 0.002-0.0034 inches.
- the composite filaments were formed into a stent suitable for biliary applications, and age hardened for up to five hours, at temperatures in the range of 900-1000° F.
- the resulting composite filaments were processed through about six cold-working and annealing cycles as in the first example, to reduce the outer filament diameter to values within the range of 0.00276 inches-0.0039 inches, and reducing the core outer diameter to values in the range of 0.0018-0.0026 inches.
- the core thus constituted 43% of the filament lateral cross-sectional area.
- the resulting filaments were formed into a small vascular stent, and age hardened for approximately three hours.
- Composite filaments were constructed and processed substantially as in example 2, except that the core was formed of a platinum nickel alloy, with nickel 10% by weight.
- the composite filaments were constructed and processed as in examples 2 and 3 , except that the core was formed of tantalum, and the case was formed of MP35N alloy, and the cold-working stages reduced the filament outer diameter to values in the range of 0.00276-0.0047 inches.
- the device has an additional layer covering the case.
- Possible materials for the additional layer include tantalum, gold, titanium, and platinum.
- the additional layer preferably has a thickness in the range of about 0.005-5.0 microns, and can be applied by methods such as thin clad overlay co-drawing, electrochemical deposition of the metal after fabrication of the composite filament, ion implantation (such as physical vapor deposition and ion beam deposition), and sputter coating.
- the additional layer is a metal having an electronegative surface such as tantalum.
- each of the above described composite filaments combines the desired structural stability and resiliency, with radio-opacity that allows in vivo imaging of the device composed of the filaments, during deployment and after device fixation. This result is achieved by a drawn filled tubing process that cold works a central core and its surrounding case, to positively bond the core and case together such that the composite filament behaves as a continuous, solid structure. Performance of the filament and resulting device is further enhanced by a selective matching of the core and case materials, as to linear thermal expansion coefficient, annealing temperature, moduli of elasticity, and crystalline structure.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Glass Compositions (AREA)
- Mechanical Coupling Of Light Guides (AREA)
- Manufacture Of Alloys Or Alloy Compounds (AREA)
- Materials For Medical Uses (AREA)
- Bending Of Plates, Rods, And Pipes (AREA)
- Gripping Jigs, Holding Jigs, And Positioning Jigs (AREA)
- Joining Of Building Structures In Genera (AREA)
- Plural Heterocyclic Compounds (AREA)
- Paper (AREA)
- Prostheses (AREA)
Abstract
A body compatible stent is formed of multiple filaments arranged in at least two sets of oppositely directed helical windings interwoven with one another in a braided configuration. Each of the filaments is a composite including a central core and a case surrounding the core. In the more preferred version, the core is formed of a radiopaque and relatively ductile material, e.g. tantalum or platinum. The outer case is formed of a relatively resilient material, e.g. a cobalt/chromium based alloy. Favorable mechanical characteristics of the stent are determined by the case, while the core enables in vivo imaging of the stent. The composite filaments are formed by a drawn filled tubing process in which the core is inserted into a tubular case of a diameter substantially more than the intended final filament diameter. The composite filament is cold-worked in several steps to reduce its diameter, and annealed between successive cold working steps. After the final cold working step, the composite filament is formed into the desired shape and age hardened. Alternative composite filaments employ an intermediate barrier layer between the case and core, a biocompatible cover layer surrounding the case, and a radiopaque case surrounding a structural core.
Description
- This patent application is a continuation-in-part of copending application Ser. No. 08/006,216, filed Jan. 19, 1993.
- The present invention relates to body implantable medical devices, and more particularly to stents and other prostheses configured for high radio-opacity as well as favorable mechanical characteristics.
- Recently several prostheses, typically of lattice work or open frame construction, have been developed for a variety of medical applications, e.g. intravascular stents for treating stenosis, prostheses for maintaining openings in the urinary tracts, biliary prostheses, esophageal stents, renal stents, and vena cava filters to counter thrombosis. One particularly well accepted device is a self-expanding mesh stent disclosed in U.S. Pat. No. 4,655,771 (Wallsten). The stent is a flexible tubular braided structure formed of helically wound thread elements. The thread elements can be constructed of a biocompatible plastic or metal, e.g. certain stainless steels, polypropylene, polyesters and polyurethanes.
- Alternatively, stents and other prostheses can be expandable by plastic deformation, usually by expanding a dilation balloon surrounded by the prosthesis. For example, U.S. Pat. No. 4,733,665 (Palmaz) discloses an intraluminal graft constructed of stainless steel strands, either woven or welded at their intersections with silver. U.S. Pat. No. 4,886,062 (Wiktor) features a balloon expandable stent constructed of stainless steel, a copper alloy, titanium, or gold.
- Regardless of whether the prosthesis is self-expanding or plastically expanded, accurate placement of the prosthesis is critical to its effective performance. Accordingly, there is a need to visually perceive the prosthesis as it is being placed within a blood vessel or other body cavity. Further, it is advantageous and sometimes necessary to visually locate and inspect a previously deployed prosthesis.
- Fluoroscopy is the prevailing technique for such visualization, and it requires radio-opacity in the materials to be imaged. The preferred structural materials for prosthesis construction, e.g. stainless steels and cobalt-based alloys, are not highly radiopaque. Consequently, prostheses constructed of these materials do not lend themselves well to fluoroscopic imaging.
- Several techniques have been proposed, in apparent recognition of this difficulty. For example, U.S. Pat. No. 4,681,110 (Wiktor) discloses a self-expanding blood vessel liner formed of woven plastic strands, radially compressed for delivery within a tube. A metal ring around the tube is radiopaque. Similarly, U.S. Pat. No. 4,830,003 (Wolff) discusses confining a radially self-expanding stent within a delivery tube, and providing radiopaque markers on the delivery tube. This approach facilitates imaging only during deployment and initial placement.
- To permit fluoroscopic imaging after placement, the stent itself must be radiopaque. The Wolff patent suggests that the stent can be formed of platinum or a platinum-iridium alloy for substantially greater radio-opacity. Such stent, however, lacks the required elasticity, and would exhibit poor resistance to fatigue. The Wiktor '110 patent teaches the attachment of metal staples to its blood vessel liner, to enhance radioopacity. However, for many applications (e.g. in blood vessels), the stent is so small that such staples either would be too small to provide useful fluoroscopic imaging, or would adversely affect the efficiency and safety of deploying the stent or other prosthesis. This Wiktor patent also suggests infusing its plastic strands with a suitable filler, e.g. gold or barium sulfate, to enhance radio-opacity. Wiktor provides no teaching as to how this might be done. Further, given the small size of prostheses intended for blood vessel placement, this technique is unlikely to materially enhance radio-opacity, due to an insufficient amount and density of the gold or barium sulfate.
- Therefore, it is an object of the present invention to provide a stent or other prosthesis with substantially enhanced radio-opacity, without any substantial reduction in the favorable mechanical properties of the prosthesis.
- Another object is to provide a resilient body insertable composite filament having a high degree of radio-opacity and favorable structural characteristics, even for stents employing relatively small diameter filaments.
- A further object is to provide a process for manufacturing a composite filament consisting essentially of a structural material for imparting desired mechanical characteristics, in combination with a radiopaque material to substantially enhance fluoroscopic imaging of the filament.
- Yet another object is to provide a case composite prosthesis in which a highly radiopaque material and a structural material cooperate to provide mechanical stability and enhanced fluoroscopic imaging, and further are selectively matched for compatibility as to their crystalline structure, coefficients of thermal expansion, and annealing temperatures.
- To achieve these and other objects, there is provided a process for manufacturing a resilient body insertable composite filament. The process includes the following steps:
- a. providing an elongate cylindrical core substantially uniform in lateral cross-section and having a core diameter, and an elongate tubular case or shell substantially uniform in lateral cross-section and having a case inside diameter, wherein one of the core and case is formed of a radiopaque material and the other is formed of a resilient material having a yield strength (0.2% offset) of at least 100,000 psi, wherein the core diameter is less than the interior diameter of the case, and the lateral cross-sectional area of the core and case is at most ten times the lateral cross-sectional area of the core;
- b. inserting the core into the case to form an elongate composite filament in which the case surrounds the core;
- c. cold-working the composite filament to reduce the lateral cross-sectional area of the composite filament by at least 15%, whereby the composite filament has a selected diameter less than an initial outside diameter of composite filament before cold-working;
- d. annealing the composite filament after cold-working, to substantially remove strain hardening and other stresses induced by the cold-working step;
- e. mechanically forming the annealed composite filament into a predetermined shape; and
- f. after the cold-working and annealing steps, and while maintaining the composite filament in the predetermined shape, age hardening the composite filament.
- In one preferred version of the process, the radiopaque material has a linear attenuation coefficient, at 100 KeV, of at least 25 cm−1. The radiopaque material forms the core, and is at least as ductile as the case. The outside diameter of the composite filament, before cold-working, preferably is at most about six millimeters (about 0.25 inches). The cold-working step can include drawing the composite filament serially through several dies, with each die plastically deforming the composite filament to reduce the outside diameter. Whenever a stage including one or more cold-working dies has reduced the cross-sectional area by at least 25%, an annealing step should be performed before any further cold-working.
- During each annealing step, the composite filament is heated to a temperature in the range of about 1700-2300° F., more preferably 1950-2150° F., for a period depending on the filament diameter, typically in the range of several seconds to several minutes. The core material and cladding (case) materials preferably are selected to have overlapping annealing temperature ranges, and similar coefficients of thermal expansion. The core and case materials further can be selectively matched as to their crystalline structure and metallurgical compatibility.
- In an alternative version of the process, the initial outside diameter of the composite structure (billet) typically is at least fifty millimeters (about two inches) in diameter. Then, before cold-working, the composite filament is subjected to temperatures in the annealing range while the outside diameter is substantially reduced, either by swaging or by pulltrusion, in successive increments until the outside diameter is at most about 6 millimeters (0.25 inches). The resulting filament is processed as before, in alternative cold-working and annealing stages.
- Further according to the process, the composite filament can be severed into a plurality of strands. Then, the strands are arranged in two oppositely directed sets of parallel helical windings about a cylindrical form, with the strands intertwined in a braided configuration to form multiple intersections. Then, while the strands are maintained in a predetermined uniform tension, they are heated to a temperature in the range of about 700-1200° F., more preferably 900-1000° F., for a time sufficient to age harden the helical windings.
- The result of this process is a resilient, body implantable prosthesis. The prosthesis has a plurality of resilient strands, helically wound in two oppositely directed sets of spaced apart and parallel strands, interwoven with one another in a braided configuration. Each of the strands includes an elongate core and an elongate tubular case surrounding the core. A cross-sectional area of the core is at least ten percent of the cross-sectional area of the strand. The core is constructed of a first material having a linear attenuation coefficient of at least 25 cm−1 at 100 KeV. The case is constructed of a resilient second material, less ductile than the first material.
- More generally, the process can be employed to form a body compatible device comprising an elongate filament substantially uniform in lateral cross-section over its length and including an elongate cylindrical core and an elongate tubular case surrounding the core. One of the core and case is constructed of a first material having a yield strength (0.2% offset) of at least twice that of the second material. The other of the core and case is constructed of a second material being radiopaque and at least as ductile as the first material.
- In a highly preferred version of the invention, the core is constructed of tantalum for radio-opacity, and the case is constructed of a cobalt-based alloy, e.g. as available under the brand names “Elgiloy”, “Phynox” and “MP35N”. The “Elgiloy” and “Thynox” alloys contain cobalt, chromium, nickel, and molybdenum, along with iron. Either of these alloys is well matched with tantalum, in terms of overlapping annealing temperature ranges, coefficients of thermal expansion and crystalline structure. The tantalum core and alloy case can be contiguous with one another, with virtually no formation of intermetallics.
- When otherwise compatible core and case materials present the risk of intermetallic formation, an intermediate layer, e.g. of tantalum, niobium, or platinum, can be formed between the core and the case to provide a barrier against intermetallic formation. Further, if the case itself is not sufficiently biocompatible, a biocompatible coating or film can surround the case. Tantalum, platinum, iridium, titanium and their alloys, or stainless steels can be used for this purpose.
- While disclosed herein in connection with a radially self-expanding stent, the composite filaments can be employed in constructing other implantable medical devices, e.g. vena cava filters, blood filters and thrombosis coils. Thus, in accordance with the present invention there is provided a resilient, body compatible prosthesis which, despite being sufficiently small for placement within blood vessels and similarly sized body cavities, has sufficient radio-opacity for fluoroscopic imaging based on the prosthesis materials themselves.
- For a further understanding of the above and other features and advantages, reference is made to the following detailed description and to the drawings, in which:
- FIG. 1 is a side elevation of a self-expanding stent constructed according to the present invention;
- FIG. 2 is an end elevational view of the stent;
- FIG. 3 is an enlarged partial view of one of the composite filaments forming the stent;
- FIG. 4 is an enlarged sectional view taken along the line4-4 in FIG. 3;
- FIGS.5-9 schematically illustrate a process for manufacturing the stent;
- FIG. 10 schematically illustrates a swaging step of an alternative process for manufacturing the stent;
- FIG. 11 is an end elevational view of an alternative embodiment filament;
- FIG. 12 is an elevational view of several components of an alternative composite filament constructed according to the present invention;
- FIG. 13 is an end elevational view of the composite filament formed by the components shown in FIG. 12; and
- FIG. 14 is an end elevational view of another alternative embodiment composite filament.
- Turning now to the drawings, there is shown in FIGS. 1 and 2 a body
implantable prosthesis 16, frequently referred to as a stent.Stent 16 is of open mesh or weave construction, consisting of two sets of oppositely directed, parallel and spaced apart helically wound strands or filaments indicated at 18 and 20, respectively. The sets of strands are interwoven in an over and under braided configuration to form multiple intersections, one of which is indicated at 22. -
Stent 16 is illustrated in its relaxed state, i.e. in the configuration it assumes when subject to no external stresses. The filaments or strands ofstent 16 are resilient, permitting a radial compression of the stent into a reduced-radius, extended-length configuration suitable for transluminal delivery of the stent to the intended placement site. As a typical example,stent 16 can have a diameter of about ten millimeters in the relaxed state, and is elastically compressed to a diameter of about 2 millimeters (0.08 inches) and an axial length of about twice the axial length of the relaxed stent. However, different applications call for different diameters. Further, it is well known to predetermine the degree of axial elongation for a given radial compression, by selectively controlling the angle between the oppositely directed helical strands. - Inelastic open-weave prostheses, expandable for example by dilation balloons, provide an alternative to resilient prostheses. Resilient or self-expanding prostheses often are preferred, as they can be deployed without dilation balloons or other stent expanding means. Self-expanding stents can be preselected according to the diameter of the blood vessel or other intended fixation site. While their deployment requires skill in stent positioning, such deployment does not require the additional skill of carefully dilating the balloon to plastically expand the prosthesis to the appropriate diameter. Further, the self-expanding stent remains at least slightly elastically compressed after fixation, and thus has a restoring force which facilitates acute fixation. By contrast, a plastically expanded stent must rely on the restoring force of deformed tissue, or on hooks, barbs, or other independent fixation elements.
- Accordingly, materials forming the strands for filaments must be strong and resilient, biocompatible, and resistant to fatigue and corrosion. Vascular applications require hemocompatibility as well. Several materials meet these needs, including stainless “spring” steels, and certain cobalt-based alloys: more particularly two alloys including cobalt, chromium, iron, nickel and molybdenum sold under the brand names “Elgiloy” (available from Carpenter Technology Corporation of Reading, Pa.) and “Phynox” (available from Metal Imphy of Imphy, France), respectively. Another suitable cobalt-chromium alloy is available under the brand name “MP35N” from Carpenter Technology Corporation of Reading, Pa. and Latrobe Steel Company, Latrobe, Pa.
- Further, it is advantageous to form a prosthesis with substantial open space to promote embedding of the stent into tissue, and fibrotic growth through the stent wall to enhance long-term fixation. A more open construction also enables substantial radial compression of the prosthesis for deployment. In a typical construction suitable for transluminal implantation, the filaments can have a diameter of about 0.1 millimeter (0.004 inches), with adjacent parallel filaments spaced apart from one another by about 1-2 millimeters (0.04-0.08 inches) when the stent is in the relaxed state.
- Fluoroecopic imaging of a conventional open weave prosthesis is extremely difficult. Due to their minute diameters and the materials involved, the filaments exhibit a relatively poor contrast to body tissue for fluoroscopic imaging purposes. The filaments also require a high degree of spatial resolution in the imaging equipment involved. Thus, a stent recognizable on X-ray film may not be distinguishable for real time imaging, due to the relatively poor spatial resolution of the video monitor as compared to X-ray film.
- According to the present invention, however, prosthesis16 is substantially more amenable to fluoroscopic imaging, due to the construction of
strands radiopaque core 24 surrounded by and concentric with an annularresilient case 26.Core 24 is highly absorptive of X-rays, preferably having a linear attenuation coefficient of at least 25 (and more preferably at least 40) cm−1 at 100 KeV. Materials with relatively high atomic numbers and densities tend to have the necessary attenuation coefficients. More particularly, it has been found that materials with an atomic number (element) or “effective” atomic number (based on a weighted average of elements in alloys or compounds) of at least fifty, and densities of at least 0.5 pounds per cubic inch, exhibit the required ability to absorb X-rays. Finally,core 24 is preferably a ductile material so that it readily conforms to the shape of the case - By contrast,
case 26 is formed of a highly resilient material, preferably with a yield strength (0.2% offset) of at least 150,000 psi. More preferably, the yield strength is at least 300,000 psi. Consequently, the mechanical behavior of composite filament 18 a in terms of elastic deformation in response to external stresses is, essentially, the behavior ofcase 26. - In addition to individual characteristics of the core and case, it is desirable to selectively match core and case materials based on certain common characteristics. The core and case materials should have the same or substantially the same linear coefficients of thermal expansion. Similarity of core and case materials in their crystalline structure is also an advantage. Finally, the core and case materials should have an overlap in their annealing temperature ranges, to facilitate manufacture of the filaments according to the process to be explained.
- In a highly preferred embodiment,
core 24 is formed of tantalum, andcase 26 is formed of a cobalt-based alloy, more particularly Elgiloy (brand) alloy. Tantalum is a ductile metal having an atomic number of 73 and a density of about 0.6 pounds per cubic inch. Its linear attenuation coefficient, at 100 KeV, is 69.7 cm−1. - The Elgiloy alloy includes principally cobalt and chromium, and has an effective atomic number of less than thirty and a density substantially less than 0.5 pounds per cubic inch. However, the alloy is body compatible, hemocompatible and highly resilient, with a yield strength (0.2% offset) of at least 350,000 psi, after cold working and age hardening.
-
Case 26 andcore 24 thus cooperate to provide a prosthesis that can be viewed in vivo, and in real time. Of course, the amount of core material in relation to the amount of case material must be sufficient to insure radio-opacity while maintaining the favorable mechanical characteristics ofstent 16. It has been found that the area ofcore 24, taken along a transverse or lateral plane as illustrated in FIG. 4, should be within the range of about ten percent to forty-six percent of the filament lateral cross-sectional area, i.e. the area of the combined case and core. - Tantalum and the Elgiloy alloy are well matched, in that the materials have similar linear coefficients of thermal expansion (3.6×10−6 per degree F. and 8.4×10−6 per degree F., respectively), similar crystalline structures, and annealing temperatures in the range of 1700-2300° F. Further, there is virtually no tendency for the formation of intermetallic compounds along the tantalum/Elgiloy alloy interface.
- Platinum and platinum alloys (e.g. platinum-iridium) also are suitable as materials for
core 24. The atomic number of platinum is 78, and its density is 0.775 pounds per cubic inch. Its linear attenuation coefficient at 100 MeV is 105 cm−1. The linear coefficient of thermal expansion for platinum is about 4.9×10−6 per degree F. - Thus, as compared to tantalum, platinum is structurally more compatible with the Elgiloy alloy, and more effectively absorbs X-rays. Accordingly, platinum is particularly well suited for use in prostheses formed of small diameter filaments. The primary disadvantage of platinum, with respect to tantalum, is its higher cost.
- Further materials suitable for
radiopaque core 24 include gold, tungsten, iridium, rhenium, ruthenium, and depleted uranium. - Other materials suitable for
case 26 include other cobalt-based alloys, e.g. the Phynox and MP35N brand alloys. Cobalt-chromium and cobalt-chromium-molybdenum orthopedic type alloys also can be employed, as well as alloys of titanium-aluminum-vanadium. The MP35N alloy is widely available, and has a potential for better fatigue strength due to improved manufacturing techniques, particularly as to the vacuum melting process. The titanium-aluminum-vanadium alloys are highly biocompatible, and have more moderate stress/strain responses, i.e. lower elastic moduli. - Composite filaments such as filament18 a are manufactured by a drawn filled tubing (DFT) process illustrated schematically in FIGS. 7-9. The DFT process can be performed, for example, by Fort Wayne Metals Research Products corporation of Ft. Wayne, Ind. The process begins with insertion of a solid cylinder or
wire 28 of the core material into acentral opening 30 of atube 32 of the case material.Core wire 28 andtubing 32 are substantially uniform in transverse or lateral sections, i.e. sections taken perpendicular to the longitudinal or axial dimension. For example,tube 32 can have an outer diameter d. of about 0.102 inch (2.6 mm) and an inner diameter d2 (diameter of opening 30) of about 0.056 inches (1.42 mm). Core orwire 28 has an outer diameter d3 slightly less than the tube inner diameter, e.g. 0.046 inches (1.17 mm). In general, the wire outer diameter is sufficiently close to the tubing inner diameter to insure that core orwire 28, upon being inserted intoopening 30, is substantially radially centered within the tubing. At the same time, the interior tubing diameter must exceed the core outside diameter sufficiently to facilitate insertion of the wire into an extended length of wire and tubing, e.g. at least twenty feet. - The values of the tubing inner diameter and the core outer diameter vary with the materials involved. For example, platinum as compared to tantalum has a smoother exterior finish when formed into the elongate wire or core. As a result, the outer diameter of a platinum wire can more closely approximate the inner diameter of the tube. Thus it is to be appreciated that the optimum diameter values vary with the materials involved, and the expected length of the composite filament.
- In any event, insertion of the core into the tube forms a
composite filament 34, which then is directed through a series of alternating cold-working and annealing steps, as indicated schematically in FIG. 6. More particularly,composite filament 34 is drawn through three dies, indicated at 36,38, and 40, respectively. In each of the dies,composite filament 34 is cold-worked in radial compression, causing thecase tube 32 and thetantalum core wire 28 to cold flow in a manner that elongates the filament while reducing its diameter. Initially,case tube 32 is elongated and radially reduced to a greater extent thancore wire 28, due to the minute radial gap that allowed the insertion of the core into the tube. However, the radial gap is closed rapidly as the filament is drawn throughdie 36, with subsequent pressure withindie 36 and the remaining dies cold-working both the core and case together as if they were a single, solid filament. In fact, upon closure of the radial gap, the cold-working within all dies forms a pressure weld along the entire interface of the core and case, to form a bond between the core and case material. - As
composite filament 34 is drawn through each die, the cold-working induces strain hardening and other stresses within the filament. Accordingly, respective heating stage is provided, i.e.furnace 42. At each annealing stage,composite filament 34 is heated to a temperature in the range of from about 1700 to about 2300° F., or more preferably 1950-2150° F. At each annealing stage, substantially all of the induced stresses are removed from the case and core, to permit further cold-working. Each annealing step is accomplished in a brief time, e.g. in as few as one to fifteen seconds at annealing temperature, depending on the size ofcomposite filament 34. - While FIG. 6 illustrates one cold-working stage and annealing stage, it is to be understood that the appropriate number of stages is selected in accordance with the final filament size, the desired degree of cross-sectional area reduction during the final cold-working stage, and the initial filament size prior to cold-working. In connection with
composite filament 34, a reduction of lateral cross-sectional area in the range of about forty percent to eighty percent is preferred, and a range of about fifty-five percent to sixty-five percent is highly preferred. - The successive cold-working and annealing steps give rise to the need for matching the core and case materials, particularly as to their coefficients of thermal expansion, elastic, moduli in tension, annealing temperature ranges, total elongation capacities, and also as to their crystalline structure. A good match of elastic moduli, elongation, and thermal expansion coefficients minimizes the tendency for any ruptures or discontinuities along the core/case interface as the composite filament is processed. Crystalline structures should be considered in matching core and case materials. The Elgiloy alloy, and other materials used to form
case tube 32, commonly experience a transformation between the cold-working and aging steps, from a face centered cubic crystalline structure to a hexagonal close packed crystalline structure. The Elgiloy alloy experiences shrinkage as it undergoes this transformation. Accordingly, the core material must either experience a similar reduction, or be sufficiently ductile to accommodate reduction of the case. - There is no annealing after the final cold-working stage. At this point,
composite filament 34 is formed into the shape intended for the device incorporating the filament. In FIG. 8, several filaments orstrands 34 a-e are helically wound about acylindrical form 48 and held in place at their opposite ends by sets ofbobbins 50 a-e and 52 a-e.Strands 34 a-e can be individually processed, or individual segments of a single annealed and cold-worked composite filament, cut after the final cold-working stage. In either event, the filaments cooperate to form one of the two oppositely directed sets of spaced apart and parallel filaments that form a device such asstent 16. While only one set of filaments is shown, it is to be understood that a corresponding group of filaments, helically wound and intertwined aboutform 48 in the opposite direction, are supported by corresponding bobbins at the opposite filament ends. - A useful prosthesis depends, in part, upon correctly supporting the filaments. The filaments are maintained in tension, and it is important to select the appropriate tensile force and apply the tensile force uniformly to all filaments. Insufficient tensile force may allow wire cast or lift effects to cause the individual filaments to depart from their helical configuration when released from the bobbins, and the braided structure of the stent may unravel.
- FIG. 9 illustrates two
filaments 34 a and 54 a, one from each of the oppositely wound filament sets, supported by respective bobbins 50 a/52 a and 56 a/58 a in afurnace 60 for age hardening in a vacuum or protective atmosphere. Age hardening is accomplished at temperatures substantially lower than annealing, e.g. in the range of about 700-1200° F., more preferably 900-1022° F. The filaments overly one another to form several intersections, one of which is indicated at 62. When the filaments are properly tensioned, slight impressions are formed in the overlying filament at each intersection. These impressions, or saddles, tend to positionally lock the filaments relative to one another at the intersections, maintaining the prosthesis configuration without the need for welding or other bonding of filaments at their intersections. - While only two oppositely directed filaments are illustrated as a matter of convenience, it is to be appreciated that the age hardening stage is performed after the winding and tensioning of all filaments, i.e. both oppositely directed sets. Accordingly, during age hardening, the filaments are locked relative to one another at multiple intersections. The preferred time for age hardening is about 1-5 hours. This age hardening step is critical to forming a satisfactory self-expanding prosthesis, as it substantially enhances elasticity, yield strength, and tensile strength. Typically, the elastic modulus is increased by at least 10% and the yield strength (0.2% offset) and tensile strength are each increased by at least 20%.
- As an alternative to the process just explained, a substantially larger and shorter composite filament64 (e.g. six inches long with a diameter of approximately ten cm) can be subjected to a series of elongation/diameter reduction steps. FIG. 10 schematically illustrates two swaging dies 66 and 68, which may be used in the course of a hot working billet reduction process. Of course, any appropriate number of swaging dies may be employed. Alternatively, the diameter reduction can be accomplished by extrusion/pulltrusion at each stage. When a sufficient number of swaging steps have reduced the composite structure diameter to about 6 millimeters (0.25 inches). The composite structure or filament can be further processed by drawing it through dies and annealing, as illustrated in FIG. 6 for the previously discussed process. As before, the composite filament is ready for selective shaping and age hardening after the final cold-working stage.
- As compared to the process depicted in FIGS.5-7, the swaging or pulltrusion approach involves substantially increased hot and cold-working of the composite structure or filament, and the initial assembling of the core into the case or shell tubing is easier. Given the much larger initial composite structure size, the structure is subjected to annealing temperatures for a substantially longer time, e.g. half an hour to an hour, as opposed to the one to fifteen second anneal times associated with the process depicted in FIG. 6. Consequently, particular care must be taken to avoid combinations of core and case materials with tendencies for intermetallic formation along the core/case interface. Further, the required hot working of the larger billet may not afford the same degree of metallurgical grain refinement.
- In general, the preferred composite filaments have: (1) sufficient radio-opacity to permit in vivo viewing; (2) the preferred mechanical properties; and (3) a sufficiently low cost. The interrelationship of these factors requires that all three be taken into account in determining filament size, relationship of
core 24 tocase 26 as to size, and materials selected for the core and case. - More particularly,
core 24 should be at least about 0.0015 inches in diameter, if a stent constructed of such filament is to be visible using conventional radiographic imaging equipment. At the same time, structural requirements (particularly elasticity for a self-expanding stent) require a minimum ratio of casing material with respect to core material. Thus, the visibility requirement effectively imposes a minimum diameter uponcase 26 as well ascore 24. Of course, appropriate selection of core and casing materials can reduce the required minimum diameters. However, potential substitute materials should be considered in view of their impact on cost—not only the material cost per se, but also as to the impact of such substitution on fabrication costs. - Several composite filament structures are particularly preferred in terms of meeting the above requirements. In the first of these structures, the core material is tantalum, and the casing is constructed of the Elgiloy brand cobalt-based alloy. The maximum outer diameter of the composite filament is about 0.150 mm, or about 0.006 inches. Elgiloy filaments of this diameter or larger may be sufficiently radiopaque without a core of tantalum or other more radiopaque material. However, even at such diameters, radio-opacity is improved with a tantalum core, and likewise with a core of a tantalum-based alloy, platinum, platinum-based alloy, tungsten, a tungsten-based alloy or combination of these constituents.
- It has been found that the preferred core size, relative to the composite fiber size, varies with the filament diameter. In particular, for larger filament (diameters of 0.100.15 mm or 0.004-0.006 inches), sufficient radio-opacity is realized when the cross-sectional area of
core 24 is about one-fourth of the cross-sectional area of the entire fiber. For smaller filaments (e.g., 0.07-0.10 mm or 0.00276-0.0039 inches such as the type often used in stents for coronary applications), the core should contribute at least about one-third of the cross-sectional area of the composite filament. Increasing the core percentage above about 33% of the filament cross-sectional area undesirably affects wire mechanical properties and stent elasticity, reducing the ability of a stent constructed of the filament to fully self-expand after its release from a delivery device. Composite filaments of this structure have core diameters in the range of 0.037-0.05 mm (0.00150-0.002 inches), with filament diameters up to about 0.135 mm or about 0.0055 inches. - In a second filament structure, the core is formed of a platinum-10% nickel alloy, i.e. 90% platinum and 10% nickel by weight. While the preferred proportion of nickel is 10%, satisfactory results can be obtained with nickel ranging from about 5% to about 15% of the alloy. The case is constructed of the Elgiloy alloy. The platinum-nickel alloy, as compared to pure tantalum, has superior radiographic and structural properties. More particularly, the alloy has a greater density, combined with a higher atomic number factor (z) for a 10-20% improvement in radio-opacity. Further as compared to tantalum, the alloy is more resistant to fatigue and thus better withstands processes for fabricating stents and other devices. Because of its superior mechanical properties, a core formed of a platinum-nickel alloy can constitute up to about 40% of the total filament cross-sectional area. Consequently the alloy is particularly well suited for constructing extremely fine filaments. This structure of composite filament is suitable for constructing stents having diameters (unstressed) in the range of about 3.5-6 mm.
- As to all composite filament structures, purity of the elements and alloys is important. Accordingly, high purity production techniques, e.g. custom melting (triple melting techniques and electron beam refining) are recommended to provide high purity Elgiloy alloy seamless tubing.
- A third filament structure involves an Elgiloy case and a core formed of a tantalum-10% tungsten alloy, although the percentage of tungsten can range from about 5% to about 20%. The tantalum/tungsten alloy is superior to tantalum in terms of mechanical strength and visibility, and costs less than the platinum-nickel alloy.
- According to a fourth filament structure,
case 26 is formed of the Elgiloy alloy, andcore 24 is formed of a platinum-20 to 30% iridium alloy. The platinum-iridium alloy can include from about 5 to about 50% iridium. As compared to the platinum-nickel alloy, the platinum-iridium alloy may exhibit less resistance to fatigue. This is due in part to segregation which may occur during cooling of an alloy containing 30% (by weight) or more iridium, due to the relatively high melting point of iridium. Also, hot working may be required if the alloy contains more than 25% iridium, thereby making final cold reduction of the composite difficult. - A fifth filament structure employs an Elgiloy alloy case and a core of a platinum-tungsten alloy having tungsten in the range of about 5-15%, and more preferably 8%. The radio-opacity of this alloy is superior to the platinum-nickel alloy and it retains the favorable mechanical characteristics.
- In a sixth filament structure, casing26 is constructed of a titanium-based alloy. More particularly, the alloy can be an alloy known as “grade 10” or “Beta 3” alloy, containing titanium along with molybdenum at 11.5%, zirconium at 6%, and tin at 4.5%. Alternatively, the titanium-based alloy can include about 13% niobium, and about 13% zirconium.
Core 24 can be formed of tantalum. More preferably, the core is formed of the platinum-10% nickel alloy. In this event, a barrier of tantalum should be formed between the core and case, as is discussed in connection with FIGS. 12 and 13. - The titanium-based alloy case is advantageous, particularly to patients exhibiting sensitivity to the nickel in the Elgiloy alloy, and may further be beneficial since it contains neither cobalt nor chrome. Also, because of the lower modulus of elasticity of the titanium-based alloy (as compared to Elgiloy), stents or other devices using the titanium-based alloy exhibit a more moderate elastic response upon release from a deployment catheter or other device. This may tend to reduce vascular neointimal hyperplasia and consequent restenosis.
- Conversely, the lower elastic modulus results in a less favorable matching of the case and core as to elasticity. In filaments utilizing the titanium-based alloy case, the proportion of core material to case material must be reduced. As a result, this construction is suitable for filaments having diameters in the range of about 0.10-0.30 mm.
- Finally, according to a seventh filament structure,
core 24 is constructed of a tungsten-based alloy including rhenium at 5-40 weight percent. More preferably, the alloy includes rhenium at about 25 percent by weight. - Further preferred materials for
core 24 include alloys of about 85-95 weight percent platinum and about 5-15 weight percent nickel: alloys including about 50-95 weight percent platinum and about 5-50 weight percent iridium; alloys including at least 80 weight percent tantalum and at most 20 weight percent tungsten; and alloys including at least 60 weight percent tungsten and at most 40 weight percent rhenium. Further suitable case materials are alloys including about 30-55 weight percent cobalt, 15-25 weight percent chromium, up to 40 weight percent nickel, 5-15 weight percent molybdenum, up to 5 weight percent manganese, and up to 25 weight percent iron. Preferably the material should have a yield strength of at least 150,000 psi (0.2% offset). While less preferred, the case material can have a yield strength of at least 100,000 psi (0.2% offset). - FIG. 11 is an end elevation of a
composite filament 74 including acentral core 76 of a structural material such as the Elgiloy alloy, surrounded by aradiopaque case 78, thus reversing the respective functions of the core and case as compared tocomposite filament 34.Composite filament 74, as compared tofilament 34, presents a larger and less refractive radiopaque profile for a given composite filament diameter.Composite filament 74, however, is more difficult to manufacture than filaments that employ the structural material as the case. - FIGS. 12 and 13 show a further alternative
composite filament 80, consisting of a centralradiopaque core 82, an outer annularstructural case 84, and an intermediateannular layer 86 between the core and the case.Intermediate layer 86 provides a barrier between the core and case, and is particularly useful in composite filaments employing core and case materials that would be incompatible if contiguous, e.g. due to a tendency to form intermetallics. Materials suitable forbarrier layer 86 include tantalum, niobium and platinum. As suggested by FIG. 12, the core, barrier layer and case can be provided as a cylinder and two tubes, inserted into one another for manufacture of the composite filament as explained above. - FIG. 14 illustrates another alternative embodiment
composite filament 88 having a centralradiopaque core 90, astructural case 92, and a relatively thin annularouter cover layer 94.Composite filament 88 is particularly useful when the selected mechanical structure lacks satisfactory biocompatibility, hemocompatibility, or both. Suitable materials forcover layer 94 include tantalum, platinum, iridium, niobium, titanium and stainless steel. The composite filament can be manufactured as explained above, beginning with insertion of the radiopaque core into the structural case, and in turn, inserting the case into a tube formed of the cover material. Alternatively,cover layer 94 can be applied by a vacuum deposition process, as a thin layer (e.g. from ten to a few hundred microns) is all that is required. - The following examples illustrate formation of composite filaments according to the above-disclosed processes.
- An elongate tantalum core having a diameter of 0.46 inches (1.17 mm) was assembled into an Elgiloy alloy case having an outer diameter of 0.102 inches (2.6 mm) and an inner diameter of 0.056 inches (1.42 mm). Accordingly, the lateral cross-sectional area of the tantalum core was about 25% of the composite filament lateral cross-sectional area. Composite filaments so constructed were subjected to 5-6 alternating stages of cold-working and annealing, to reduce the outer diameters of the composite filaments to values within the range of 0.004-0.0067 inches. The tantalum core diameters were reduced to values in the range of 0.002-0.0034 inches. The composite filaments were formed into a stent suitable for biliary applications, and age hardened for up to five hours, at temperatures in the range of 900-1000° F.
- Elongate cores of a platinum iridium alloy (20% by weight iridium), with initial core outer diameters of 0.088 inches, were inserted into annular Elgiloy cases with outer diameters of 0.144 inches and inside diameters of 0.098 inches. The resulting composite filaments were processed through about six cold-working and annealing cycles as in the first example, to reduce the outer filament diameter to values within the range of 0.00276 inches-0.0039 inches, and reducing the core outer diameter to values in the range of 0.0018-0.0026 inches. The core thus constituted 43% of the filament lateral cross-sectional area. The resulting filaments were formed into a small vascular stent, and age hardened for approximately three hours.
- Composite filaments were constructed and processed substantially as in example 2, except that the core was formed of a platinum nickel alloy, with nickel 10% by weight.
- The composite filaments were constructed and processed as in examples2 and 3, except that the core was formed of tantalum, and the case was formed of MP35N alloy, and the cold-working stages reduced the filament outer diameter to values in the range of 0.00276-0.0047 inches.
- In the case of all examples above, the resulting stents exhibited satisfactory elasticity and were readily fluoroscopically imaged in real time.
- In other embodiments, the device has an additional layer covering the case. Possible materials for the additional layer include tantalum, gold, titanium, and platinum. The additional layer preferably has a thickness in the range of about 0.005-5.0 microns, and can be applied by methods such as thin clad overlay co-drawing, electrochemical deposition of the metal after fabrication of the composite filament, ion implantation (such as physical vapor deposition and ion beam deposition), and sputter coating. Preferably the additional layer is a metal having an electronegative surface such as tantalum.
- Each of the above described composite filaments combines the desired structural stability and resiliency, with radio-opacity that allows in vivo imaging of the device composed of the filaments, during deployment and after device fixation. This result is achieved by a drawn filled tubing process that cold works a central core and its surrounding case, to positively bond the core and case together such that the composite filament behaves as a continuous, solid structure. Performance of the filament and resulting device is further enhanced by a selective matching of the core and case materials, as to linear thermal expansion coefficient, annealing temperature, moduli of elasticity, and crystalline structure.
Claims (26)
1. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the case is constructed of a case material having a yield strength of at least 100,000 psi (0.2% offset), and the core is constructed of a core material comprising at least one of the following constituents: tantalum, a tantalum-based alloy, platinum, and a platinum-based alloy, tungsten, and a tungsten-based alloy.
2. The device of claim 1 wherein:
said tantalum alloy comprises tungsten at about 5 to about 20%, by weight.
3. The device of claim 2 wherein:
said tantalum alloy includes tungsten at about 10%.
4. The device of claim 2 wherein:
said case material comprising a cobalt-based alloy.
5. The device of claim 2 wherein:
said case material comprising a titanium-based alloy.
6. The device of claim 5 further including:
an intermediate layer forming a barrier between the core and the case.
7. The device of claim 1 wherein:
said platinum alloy includes at least one of the following constituents: nickel at about from 5 to 15%; iridium at about from 5 to 50% and tungsten at about from 5 to 15%.
8. The device of claim 1 wherein:
said platinum alloy includes at least one of the following constituents: nickel at about 10%; iridium at about 20-30%; and tungsten at about 8%.
9. The device of claim 1 wherein:
said tungsten-based alloy comprises rhenium at 5-40 percent, by weight.
10. The device of claim 9 wherein:
said tungsten-based alloy comprises rhenium at about 25 percent, by weight.
11. The device of claim 1 wherein:
the case and the core are contiguous.
12. A resilient, body implantable prosthesis including a plurality of the elongate filaments as defined in claim 1 , wherein:
said elongate filaments are helically wound in at least two oppositely directed sets of spaced apart filaments, with said sets of filaments interwoven with one another in a braided configuration.
13. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core is constructed of a core material having a linear attenuation coefficient of at least 25 cm−1 at 100 KeV, and the case is constructed of a case material, said core material being more ductile and more radiopaque than the case material, and wherein the case material comprising a titanium-based alloy.
14. The device of claim 13 wherein:
said titanium-based alloy includes niobium at about from 10 to 15%, and zirconium at about from to 10 to 15%.
15. The device of claim 14 wherein:
said titanium-based alloy includes about 13% niobium, and about 13% zirconium.
16. The device of claim 13 wherein:
said titanium-based alloy further includes molybdenum, zirconium, and tin.
17. The device of claim 16 wherein:
said titanium-based alloy includes molybdenum at about 11.5%, zirconium at about 6%, and tin at about 4.5%.
18. The device of claim 13 wherein:
said core material comprising one of the following constituents: tantalum, a tantalum-based alloy, and a platinum-based alloy.
19. The device of claim 18 wherein:
said core material comprising a platinum-based alloy.
20. The device of claim 19 further including:
an intermediate layer forming a barrier between the core and the case.
21. A resilient, body implantable prosthesis including a plurality of the elongate filaments as defined in claim 13 , wherein:
said elongate filaments are helically wound in at least two oppositely directed sets of spaced apart filaments, with said sets of filaments interwoven with one another in a braided configuration.
22. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core is formed of a core material comprising an essentially unalloyed tantalum and the case is formed of a case material comprising about 30-55 weight percent cobalt, about 15-25 weight percent chromium, about 0-40 weight percent nickel, about 5-15 weight percent molybdenum, about 0-5 weight percent manganese, and about 0-25 weight percent iron.
23. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core material comprises about 85-95 weight percent platinum and about 5-15 weight percent nickel, and the case is formed of a case material comprising about 30-55 weight percent cobalt, about 15-25 weight percent chromium, about 0-40 weight percent nickel, about 5-15 weight percent molybdenum, about 0-5 weight percent manganese, and about 0-25 weight percent iron.
24. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core is formed of a core material comprising about 50-95 weight percent platinum and about 5-50 weight percent iridium, and the case is formed of a case material comprising about 30-55 weight percent cobalt, about 15-25 weight percent chromium, about 0-40 weight percent nickel, about 5-15 weight percent molybdenum, about 0-5 weight percent manganese, and about 0-25 weight percent iron.
25. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core is formed of a core material comprising about 80-100 weight percent tantalum and about 0-20 weight percent tungsten, and the case is formed of a case material comprising about 30-55 weight percent cobalt, about 15-25 weight percent chromium, about 0-40 weight percent nickel, about 5-15 weight percent molybdenum, about 0-5 weight percent manganese, and about 0-25 weight percent iron.
26. A body compatible device comprising:
an elongate filament substantially uniform in lateral cross-section over its length and including an elongate core and an elongate case surrounding the core;
wherein the core is formed of a core material comprising about 60-100 weight percent tungsten and about 0-40 weight percent rhenium.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/175,254 US20030009215A1 (en) | 1993-01-19 | 2002-06-19 | Clad composite stent |
US10/971,742 US20050059889A1 (en) | 1996-10-16 | 2004-10-22 | Clad composite stent |
US12/495,155 US20090276033A1 (en) | 1993-01-19 | 2009-06-30 | Clad Composite Stent |
US13/042,211 US20110160842A1 (en) | 1993-01-19 | 2011-03-07 | Clad Composite Stent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US621693A | 1993-01-19 | 1993-01-19 | |
US08/935,694 US6527802B1 (en) | 1993-01-19 | 1997-09-23 | Clad composite stent |
US10/175,254 US20030009215A1 (en) | 1993-01-19 | 2002-06-19 | Clad composite stent |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US73220796A Continuation | 1993-01-19 | 1996-10-16 | |
US08/935,694 Continuation US6527802B1 (en) | 1993-01-19 | 1997-09-23 | Clad composite stent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/971,742 Continuation US20050059889A1 (en) | 1993-01-19 | 2004-10-22 | Clad composite stent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030009215A1 true US20030009215A1 (en) | 2003-01-09 |
Family
ID=21719832
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/469,810 Expired - Lifetime US5824077A (en) | 1993-01-19 | 1995-06-06 | Clad composite stent |
US08/485,626 Expired - Lifetime US5800511A (en) | 1993-01-19 | 1995-06-07 | Clad composite stent |
US08/480,121 Expired - Lifetime US5628787A (en) | 1993-01-19 | 1995-06-07 | Clad composite stent |
US08/764,130 Expired - Lifetime US5679470A (en) | 1993-01-19 | 1996-12-12 | Process for manufacturing clad composite stent |
US10/175,254 Abandoned US20030009215A1 (en) | 1993-01-19 | 2002-06-19 | Clad composite stent |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/469,810 Expired - Lifetime US5824077A (en) | 1993-01-19 | 1995-06-06 | Clad composite stent |
US08/485,626 Expired - Lifetime US5800511A (en) | 1993-01-19 | 1995-06-07 | Clad composite stent |
US08/480,121 Expired - Lifetime US5628787A (en) | 1993-01-19 | 1995-06-07 | Clad composite stent |
US08/764,130 Expired - Lifetime US5679470A (en) | 1993-01-19 | 1996-12-12 | Process for manufacturing clad composite stent |
Country Status (16)
Country | Link |
---|---|
US (5) | US5824077A (en) |
EP (1) | EP0773751B1 (en) |
JP (1) | JP2746755B2 (en) |
KR (2) | KR0147482B1 (en) |
AT (1) | ATE207728T1 (en) |
AU (2) | AU673878B2 (en) |
BR (1) | BR9307814A (en) |
CA (1) | CA2152594C (en) |
DE (1) | DE69331069T2 (en) |
ES (1) | ES2166370T3 (en) |
FI (1) | FI953472A0 (en) |
IL (2) | IL108325A (en) |
NO (1) | NO952852L (en) |
TW (1) | TW234689B (en) |
WO (1) | WO1994016646A1 (en) |
ZA (1) | ZA94334B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048825A1 (en) * | 2001-10-10 | 2004-03-11 | Monia Brett P. | Antisense modulation of CREB expression |
US20040236433A1 (en) * | 2003-05-23 | 2004-11-25 | Kennedy Richard L. | Cobalt alloys, methods of making cobalt alloys, and implants and articles of manufacture made therefrom |
US20060089568A1 (en) * | 2001-01-12 | 2006-04-27 | Mx Medical, Inc. | Titanium molybdenum alloy guidewire |
EP1655384A1 (en) * | 2004-11-09 | 2006-05-10 | Cordis Corporation | A cobalt-chromium-molybdenum fatigue resistant alloy for intravascular medical devices |
US20060153729A1 (en) * | 2005-01-13 | 2006-07-13 | Stinson Jonathan S | Medical devices and methods of making the same |
US20070067009A1 (en) * | 2003-11-07 | 2007-03-22 | Deepak Gandhi | Implantable medical devices with enhanced visibility, mechanical properties and biocompatability |
US20110060400A1 (en) * | 2005-03-14 | 2011-03-10 | Abbott Laboratories | Visible endoprosthesis |
US20120239157A1 (en) * | 2007-08-20 | 2012-09-20 | Depuy Products, Inc. | Ultra-passivation of chromium containing alloy and methods of producing same |
US8414635B2 (en) | 1999-02-01 | 2013-04-09 | Idev Technologies, Inc. | Plain woven stents |
US8419788B2 (en) | 2006-10-22 | 2013-04-16 | Idev Technologies, Inc. | Secured strand end devices |
US20140018843A1 (en) * | 2004-05-25 | 2014-01-16 | Covidien Lp | Methods and apparatus for luminal stenting |
US8876881B2 (en) | 2006-10-22 | 2014-11-04 | Idev Technologies, Inc. | Devices for stent advancement |
US9023095B2 (en) | 2010-05-27 | 2015-05-05 | Idev Technologies, Inc. | Stent delivery system with pusher assembly |
US9114001B2 (en) | 2012-10-30 | 2015-08-25 | Covidien Lp | Systems for attaining a predetermined porosity of a vascular device |
US9125659B2 (en) | 2004-05-25 | 2015-09-08 | Covidien Lp | Flexible vascular occluding device |
US9157174B2 (en) | 2013-02-05 | 2015-10-13 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9320590B2 (en) | 2006-02-22 | 2016-04-26 | Covidien Lp | Stents having radiopaque mesh |
US20160151179A1 (en) * | 2013-06-21 | 2016-06-02 | Universite Joseph Fourier | Stent spacer |
US9393021B2 (en) | 2004-05-25 | 2016-07-19 | Covidien Lp | Flexible vascular occluding device |
US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9943427B2 (en) | 2012-11-06 | 2018-04-17 | Covidien Lp | Shaped occluding devices and methods of using the same |
US10004618B2 (en) | 2004-05-25 | 2018-06-26 | Covidien Lp | Methods and apparatus for luminal stenting |
WO2022002281A1 (en) * | 2020-06-30 | 2022-01-06 | 微创神通医疗科技(上海)有限公司 | Vascular stent |
Families Citing this family (310)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309487B1 (en) * | 1989-11-28 | 2001-10-30 | Robert M. Herrin | Disposable garments and method and apparatus for making |
US7101392B2 (en) * | 1992-03-31 | 2006-09-05 | Boston Scientific Corporation | Tubular medical endoprostheses |
US6497709B1 (en) | 1992-03-31 | 2002-12-24 | Boston Scientific Corporation | Metal medical device |
WO1993019803A1 (en) * | 1992-03-31 | 1993-10-14 | Boston Scientific Corporation | Medical wire |
US20050059889A1 (en) * | 1996-10-16 | 2005-03-17 | Schneider (Usa) Inc., A Minnesota Corporation | Clad composite stent |
US5630840A (en) | 1993-01-19 | 1997-05-20 | Schneider (Usa) Inc | Clad composite stent |
EP0758870A1 (en) * | 1994-05-09 | 1997-02-26 | Schneider (Usa) Inc. | Clad composite stent |
US5636641A (en) * | 1994-07-25 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | High strength member for intracorporeal use |
US6736843B1 (en) * | 1994-07-25 | 2004-05-18 | Advanced Cardiovascular Systems, Inc. | Cylindrically-shaped balloon-expandable stent |
US6245068B1 (en) | 1994-08-08 | 2001-06-12 | Scimed Life Systems, Inc. | Resilient radiopaque electrophysiology electrodes and probes including the same |
IL115755A0 (en) * | 1994-10-27 | 1996-01-19 | Medinol Ltd | X-ray visible stent |
ATE192346T1 (en) * | 1995-06-22 | 2000-05-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF A BODY VESSEL USING IONIZATION RADIATION |
US6329069B1 (en) * | 1995-07-26 | 2001-12-11 | Surface Genesis, Inc. | Composite structure and devices made from same and method |
US5758562A (en) * | 1995-10-11 | 1998-06-02 | Schneider (Usa) Inc. | Process for manufacturing braided composite prosthesis |
ATE177928T1 (en) * | 1995-11-14 | 1999-04-15 | Schneider Europ Gmbh | DEVICE FOR STENT IMPLANTATION |
JPH09215753A (en) * | 1996-02-08 | 1997-08-19 | Schneider Usa Inc | Self-expanding stent made of titanium alloy |
US6796997B1 (en) | 1996-03-05 | 2004-09-28 | Evysio Medical Devices Ulc | Expandable stent |
CA2192520A1 (en) * | 1996-03-05 | 1997-09-05 | Ian M. Penn | Expandable stent and method for delivery of same |
EP1477133B9 (en) | 1996-03-05 | 2007-11-21 | Evysio Medical Devices Ulc | Expandable stent |
US6334871B1 (en) | 1996-03-13 | 2002-01-01 | Medtronic, Inc. | Radiopaque stent markers |
IL117472A0 (en) | 1996-03-13 | 1996-07-23 | Instent Israel Ltd | Radiopaque stent markers |
US5891191A (en) * | 1996-04-30 | 1999-04-06 | Schneider (Usa) Inc | Cobalt-chromium-molybdenum alloy stent and stent-graft |
US6592617B2 (en) | 1996-04-30 | 2003-07-15 | Boston Scientific Scimed, Inc. | Three-dimensional braided covered stent |
US6027528A (en) * | 1996-05-28 | 2000-02-22 | Cordis Corporation | Composite material endoprosthesis |
US5733326A (en) * | 1996-05-28 | 1998-03-31 | Cordis Corporation | Composite material endoprosthesis |
US6174329B1 (en) * | 1996-08-22 | 2001-01-16 | Advanced Cardiovascular Systems, Inc. | Protective coating for a stent with intermediate radiopaque coating |
JP2000501328A (en) * | 1996-10-01 | 2000-02-08 | ヌームド インコーポレーテッド | Expandable stent |
US6387121B1 (en) * | 1996-10-21 | 2002-05-14 | Inflow Dynamics Inc. | Vascular and endoluminal stents with improved coatings |
US6099561A (en) * | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
EP0850654A1 (en) | 1996-12-20 | 1998-07-01 | Schneider (Usa) Inc. | Implantable device sensing catheter |
US5858556A (en) * | 1997-01-21 | 1999-01-12 | Uti Corporation | Multilayer composite tubular structure and method of making |
US5957974A (en) * | 1997-01-23 | 1999-09-28 | Schneider (Usa) Inc | Stent graft with braided polymeric sleeve |
US8353948B2 (en) | 1997-01-24 | 2013-01-15 | Celonova Stent, Inc. | Fracture-resistant helical stent incorporating bistable cells and methods of use |
US6726829B2 (en) | 1997-04-08 | 2004-04-27 | Scimed Life Systems, Inc. | Method of manufacturing a stent |
DE69837704T2 (en) * | 1997-04-15 | 2007-09-06 | Schneider (Usa) Inc., Plymouth | Prosthesis with selected welded crossed threads |
CA2424551A1 (en) * | 1997-05-27 | 1998-11-27 | Schneider (Usa) Inc. | Stent and stent-graft for treating branched vessels |
US5906641A (en) | 1997-05-27 | 1999-05-25 | Schneider (Usa) Inc | Bifurcated stent graft |
ATE286687T1 (en) * | 1997-07-17 | 2005-01-15 | Schneider Europ Gmbh | STENT AND PRODUCTION METHOD THEREOF |
US6245103B1 (en) | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US6340367B1 (en) | 1997-08-01 | 2002-01-22 | Boston Scientific Scimed, Inc. | Radiopaque markers and methods of using the same |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US5980564A (en) * | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6156061A (en) * | 1997-08-29 | 2000-12-05 | Target Therapeutics, Inc. | Fast-detaching electrically insulated implant |
NO311781B1 (en) * | 1997-11-13 | 2002-01-28 | Medinol Ltd | Metal multilayer stents |
US6168570B1 (en) | 1997-12-05 | 2001-01-02 | Micrus Corporation | Micro-strand cable with enhanced radiopacity |
US6159165A (en) | 1997-12-05 | 2000-12-12 | Micrus Corporation | Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand |
US5976169A (en) * | 1997-12-16 | 1999-11-02 | Cardiovasc, Inc. | Stent with silver coating and method |
US6626939B1 (en) * | 1997-12-18 | 2003-09-30 | Boston Scientific Scimed, Inc. | Stent-graft with bioabsorbable structural support |
US6296633B1 (en) * | 1998-01-09 | 2001-10-02 | Schneider (Usa) Inc. | Medical device tubing assembly and method of making the same |
US20040254635A1 (en) * | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7208010B2 (en) * | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US5980566A (en) * | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US6238340B1 (en) * | 1998-05-19 | 2001-05-29 | Eckhard Alt | Composite materials for avoidance of unwanted radiation amplification |
DE29810483U1 (en) | 1998-06-12 | 1999-10-14 | Micro Science Medical AG, 75443 Ötisheim | Surface implantation or surface coating for stents or other implants |
WO1999065623A1 (en) * | 1998-06-15 | 1999-12-23 | Scimed Life Systems, Inc. | Process of making composite stents with gold alloy cores |
US6387060B1 (en) | 1998-06-17 | 2002-05-14 | Advanced Cardiovascular Systems, Inc. | Composite radiopaque intracorporeal product |
US6139511A (en) * | 1998-06-29 | 2000-10-31 | Advanced Cardiovascular Systems, Inc. | Guidewire with variable coil configuration |
US6171297B1 (en) | 1998-06-30 | 2001-01-09 | Schneider (Usa) Inc | Radiopaque catheter tip |
US6217609B1 (en) | 1998-06-30 | 2001-04-17 | Schneider (Usa) Inc | Implantable endoprosthesis with patterned terminated ends and methods for making same |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
US8070796B2 (en) * | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7004962B2 (en) | 1998-07-27 | 2006-02-28 | Schneider (Usa), Inc. | Neuroaneurysm occlusion and delivery device and method of using same |
US6156064A (en) | 1998-08-14 | 2000-12-05 | Schneider (Usa) Inc | Stent-graft-membrane and method of making the same |
US6364902B1 (en) * | 1998-10-05 | 2002-04-02 | Noble-Met, Ltd. | Metal composite tube for biomedical applications |
US6475234B1 (en) | 1998-10-26 | 2002-11-05 | Medinol, Ltd. | Balloon expandable covered stents |
US6293967B1 (en) | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6290692B1 (en) | 1998-11-03 | 2001-09-18 | Daniel J. Klima | Catheter support structure |
US6234981B1 (en) | 1998-12-30 | 2001-05-22 | Advanced Cardiovascular Systems, Inc. | Vapor deposition coated intracorporeal device |
US7717864B1 (en) | 1998-12-31 | 2010-05-18 | Advanced Cardiovascular Systems, Inc. | Composite guidewire with drawn and filled tube construction |
US7645242B1 (en) * | 1998-12-31 | 2010-01-12 | Advanced Cardiovascular Systems, Inc. | Composite guidewire with drawn and filled tube construction |
US6142975A (en) | 1998-12-31 | 2000-11-07 | Advanced Cardiovascular Systems, Inc. | Guidewire having braided wire over drawn tube construction |
US6620192B1 (en) | 1999-03-16 | 2003-09-16 | Advanced Cardiovascular Systems, Inc. | Multilayer stent |
US6464723B1 (en) | 1999-04-22 | 2002-10-15 | Advanced Cardiovascular Systems, Inc. | Radiopaque stents |
US6726712B1 (en) * | 1999-05-14 | 2004-04-27 | Boston Scientific Scimed | Prosthesis deployment device with translucent distal end |
US6290673B1 (en) | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US6585757B1 (en) | 1999-09-15 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Endovascular stent with radiopaque spine |
US6334868B1 (en) | 1999-10-08 | 2002-01-01 | Advanced Cardiovascular Systems, Inc. | Stent cover |
US6387123B1 (en) * | 1999-10-13 | 2002-05-14 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque core |
US6295476B1 (en) | 1999-11-01 | 2001-09-25 | Medtronic, Inc. | Medical lead conductor fracture visualization method and apparatus |
US6679910B1 (en) | 1999-11-12 | 2004-01-20 | Latin American Devices Llc | Intraluminal stent |
US6475235B1 (en) | 1999-11-16 | 2002-11-05 | Iowa-India Investments Company, Limited | Encapsulated stent preform |
US6508832B1 (en) | 1999-12-09 | 2003-01-21 | Advanced Cardiovascular Systems, Inc. | Implantable nickel-free stainless steel stents and method of making the same |
US7250058B1 (en) | 2000-03-24 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Radiopaque intraluminal stent |
AU2001267075A1 (en) * | 2000-06-13 | 2001-12-24 | Scimed Life Systems, Inc. | Disintegrating stent and method of making same |
US6652579B1 (en) | 2000-06-22 | 2003-11-25 | Advanced Cardiovascular Systems, Inc. | Radiopaque stent |
US20030018380A1 (en) * | 2000-07-07 | 2003-01-23 | Craig Charles H. | Platinum enhanced alloy and intravascular or implantable medical devices manufactured therefrom |
US6799637B2 (en) | 2000-10-20 | 2004-10-05 | Schlumberger Technology Corporation | Expandable tubing and method |
CA2419379C (en) | 2000-08-15 | 2011-10-11 | Surmodics, Inc. | Medicament incorporation matrix |
GB0020491D0 (en) | 2000-08-18 | 2000-10-11 | Angiomed Ag | Stent with attached element and method of making such a stent |
US6649030B1 (en) | 2000-08-31 | 2003-11-18 | Endovascular Technologies, Inc. | Physical vapor deposition of radiopaque markings on a graft |
US7101391B2 (en) * | 2000-09-18 | 2006-09-05 | Inflow Dynamics Inc. | Primarily niobium stent |
US7402173B2 (en) * | 2000-09-18 | 2008-07-22 | Boston Scientific Scimed, Inc. | Metal stent with surface layer of noble metal oxide and method of fabrication |
US6652574B1 (en) | 2000-09-28 | 2003-11-25 | Vascular Concepts Holdings Limited | Product and process for manufacturing a wire stent coated with a biocompatible fluoropolymer |
US6492615B1 (en) | 2000-10-12 | 2002-12-10 | Scimed Life Systems, Inc. | Laser polishing of medical devices |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
EP1582180B1 (en) | 2000-10-16 | 2008-02-27 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6641776B1 (en) * | 2000-11-15 | 2003-11-04 | Scimed Life Systems, Inc. | Method for preparing radiopaque surgical implement |
US7077837B2 (en) * | 2000-11-20 | 2006-07-18 | Implant Sciences Corporation | Multi-layered radiopaque coating on intravascular devices |
EP1337286A1 (en) | 2000-11-28 | 2003-08-27 | Fortimedix B.V. | Stent |
US8870946B1 (en) | 2000-12-11 | 2014-10-28 | W.L. Gore & Associates, Inc. | Method of deploying a bifurcated side-access intravascular stent graft |
US6645242B1 (en) | 2000-12-11 | 2003-11-11 | Stephen F. Quinn | Bifurcated side-access intravascular stent graft |
US6569194B1 (en) | 2000-12-28 | 2003-05-27 | Advanced Cardiovascular Systems, Inc. | Thermoelastic and superelastic Ni-Ti-W alloy |
US6641607B1 (en) | 2000-12-29 | 2003-11-04 | Advanced Cardiovascular Systems, Inc. | Double tube stent |
US20020095205A1 (en) * | 2001-01-12 | 2002-07-18 | Edwin Tarun J. | Encapsulated radiopaque markers |
NO335594B1 (en) | 2001-01-16 | 2015-01-12 | Halliburton Energy Serv Inc | Expandable devices and methods thereof |
US6964680B2 (en) * | 2001-02-05 | 2005-11-15 | Conor Medsystems, Inc. | Expandable medical device with tapered hinge |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
RU2200205C2 (en) * | 2001-03-05 | 2003-03-10 | Гюнтер Виктор Эдуардович | Porous permeable alloy on base of titanium nickelide |
US20020138136A1 (en) * | 2001-03-23 | 2002-09-26 | Scimed Life Systems, Inc. | Medical device having radio-opacification and barrier layers |
US7044958B2 (en) | 2001-04-03 | 2006-05-16 | Medtronic Vascular, Inc. | Temporary device for capturing embolic material |
US6818006B2 (en) | 2001-04-03 | 2004-11-16 | Medtronic Vascular, Inc. | Temporary intraluminal filter guidewire |
US6866677B2 (en) * | 2001-04-03 | 2005-03-15 | Medtronic Ave, Inc. | Temporary intraluminal filter guidewire and methods of use |
US6974480B2 (en) | 2001-05-03 | 2005-12-13 | Synthes (Usa) | Intervertebral implant for transforaminal posterior lumbar interbody fusion procedure |
US6719794B2 (en) | 2001-05-03 | 2004-04-13 | Synthes (U.S.A.) | Intervertebral implant for transforaminal posterior lumbar interbody fusion procedure |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US6926733B2 (en) * | 2001-08-02 | 2005-08-09 | Boston Scientific Scimed, Inc. | Method for enhancing sheet or tubing metal stent radiopacity |
US7056338B2 (en) | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US6908480B2 (en) | 2001-08-29 | 2005-06-21 | Swaminathan Jayaraman | Structurally variable stents |
US20060004437A1 (en) * | 2001-08-29 | 2006-01-05 | Swaminathan Jayaraman | Structurally variable stents |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US20030060872A1 (en) * | 2001-09-26 | 2003-03-27 | Gary Gomringer | Stent with radiopaque characteristics |
US6893431B2 (en) | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US7445629B2 (en) | 2002-01-31 | 2008-11-04 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US20030181972A1 (en) * | 2002-03-22 | 2003-09-25 | Scimed Life Systems, Inc. | MRI and x-ray compatible stent material |
US6780261B2 (en) * | 2002-06-27 | 2004-08-24 | Scimed Life Systems, Inc. | Method of manufacturing an implantable stent having improved mechanical properties |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US7357854B1 (en) | 2002-08-19 | 2008-04-15 | Advanced Cardiovascular Systems, Inc. | Process for electropolishing a device made from cobalt-chromium |
US7029495B2 (en) * | 2002-08-28 | 2006-04-18 | Scimed Life Systems, Inc. | Medical devices and methods of making the same |
US20040049261A1 (en) * | 2002-09-09 | 2004-03-11 | Yixin Xu | Medical devices |
US20040127976A1 (en) * | 2002-09-20 | 2004-07-01 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
DE10245516B4 (en) * | 2002-09-27 | 2004-09-30 | W. C. Heraeus Gmbh & Co. Kg | Alloy for use with stents |
US6814746B2 (en) | 2002-11-01 | 2004-11-09 | Ev3 Peripheral, Inc. | Implant delivery system with marker interlock |
US20040143317A1 (en) * | 2003-01-17 | 2004-07-22 | Stinson Jonathan S. | Medical devices |
US20040181208A1 (en) * | 2003-03-14 | 2004-09-16 | Poole Matthew S. | Catheter reinforced with high yield strength wire |
US7792568B2 (en) * | 2003-03-17 | 2010-09-07 | Boston Scientific Scimed, Inc. | MRI-visible medical devices |
US7220274B1 (en) | 2003-03-21 | 2007-05-22 | Quinn Stephen F | Intravascular stent grafts and methods for deploying the same |
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
DE10317241A1 (en) * | 2003-04-10 | 2004-10-28 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | stent |
US20040204737A1 (en) * | 2003-04-11 | 2004-10-14 | Scimed Life Systems, Inc. | Embolic filter loop fabricated from composite material |
US7789979B2 (en) * | 2003-05-02 | 2010-09-07 | Gore Enterprise Holdings, Inc. | Shape memory alloy articles with improved fatigue performance and methods therefor |
US7015392B1 (en) * | 2003-05-28 | 2006-03-21 | Accellent, Inc. | High torsional ductility wire and methods of making the same |
US7169179B2 (en) * | 2003-06-05 | 2007-01-30 | Conor Medsystems, Inc. | Drug delivery device and method for bi-directional drug delivery |
JP4798662B2 (en) * | 2003-06-13 | 2011-10-19 | ゲーカーエスエスフォルシュングスツェントゥルム ゲーストハハト ゲーエムベーハー | Stent |
US7326571B2 (en) | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
US20050055080A1 (en) * | 2003-09-05 | 2005-03-10 | Naim Istephanous | Modulated stents and methods of making the stents |
US20050060025A1 (en) * | 2003-09-12 | 2005-03-17 | Mackiewicz David A. | Radiopaque markers for medical devices |
US7488343B2 (en) * | 2003-09-16 | 2009-02-10 | Boston Scientific Scimed, Inc. | Medical devices |
US7785653B2 (en) * | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US7020947B2 (en) * | 2003-09-23 | 2006-04-04 | Fort Wayne Metals Research Products Corporation | Metal wire with filaments for biomedical applications |
US7329383B2 (en) * | 2003-10-22 | 2008-02-12 | Boston Scientific Scimed, Inc. | Alloy compositions and devices including the compositions |
US7854756B2 (en) * | 2004-01-22 | 2010-12-21 | Boston Scientific Scimed, Inc. | Medical devices |
DE102004008459A1 (en) * | 2004-02-17 | 2005-09-01 | Aesculap Ag & Co. Kg | Implant, useful as stents, comprises a fabric and at least a radiopaque marker, which passes in a direction along the implant |
US8137397B2 (en) | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
US7761138B2 (en) * | 2004-03-12 | 2010-07-20 | Boston Scientific Scimed, Inc. | MRI and X-ray visualization |
US8500751B2 (en) | 2004-03-31 | 2013-08-06 | Merlin Md Pte Ltd | Medical device |
US20050288655A1 (en) * | 2004-06-29 | 2005-12-29 | Howard Root | Laser fiber for endovenous therapy having a shielded distal tip |
US20060025848A1 (en) * | 2004-07-29 | 2006-02-02 | Jan Weber | Medical device having a coating layer with structural elements therein and method of making the same |
WO2006024491A1 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
US7628807B2 (en) * | 2004-11-04 | 2009-12-08 | Boston Scientific Scimed, Inc. | Stent for delivering a therapeutic agent having increased body tissue contact surface |
US20060129240A1 (en) * | 2004-12-10 | 2006-06-15 | Joe Lessar | Implants based on engineered composite materials having enhanced imaging and wear resistance |
US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US7488444B2 (en) | 2005-03-03 | 2009-02-10 | Icon Medical Corp. | Metal alloys for medical devices |
WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US7540995B2 (en) * | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US7452502B2 (en) * | 2005-03-03 | 2008-11-18 | Icon Medical Corp. | Metal alloy for a stent |
US7309353B2 (en) * | 2005-04-29 | 2007-12-18 | Medtronic Vascular, Inc. | Use of platinum group metals in vascular devices and method of texturing platinum group metals |
US20070118207A1 (en) * | 2005-05-04 | 2007-05-24 | Aga Medical Corporation | System for controlled delivery of stents and grafts |
US20060253184A1 (en) * | 2005-05-04 | 2006-11-09 | Kurt Amplatz | System for the controlled delivery of stents and grafts |
US20060259126A1 (en) * | 2005-05-05 | 2006-11-16 | Jason Lenz | Medical devices and methods of making the same |
US20060276910A1 (en) * | 2005-06-01 | 2006-12-07 | Jan Weber | Endoprostheses |
WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US20070073374A1 (en) * | 2005-09-29 | 2007-03-29 | Anderl Steven F | Endoprostheses including nickel-titanium alloys |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
KR100758739B1 (en) * | 2006-03-15 | 2007-09-14 | 주식회사 제노스 | Cardiovascular stent |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
JP5078271B2 (en) | 2006-03-30 | 2012-11-21 | テルモ株式会社 | Stent for living body expansion and method for manufacturing the same |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US7879086B2 (en) | 2006-04-20 | 2011-02-01 | Boston Scientific Scimed, Inc. | Medical device having a coating comprising an adhesion promoter |
US7955383B2 (en) * | 2006-04-25 | 2011-06-07 | Medtronics Vascular, Inc. | Laminated implantable medical device having a metallic coating |
PL2019657T3 (en) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Coatings containing multiple drugs |
GB0609841D0 (en) | 2006-05-17 | 2006-06-28 | Angiomed Ag | Bend-capable tubular prosthesis |
GB0609911D0 (en) | 2006-05-18 | 2006-06-28 | Angiomed Ag | Bend-capable stent prosthesis |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
JP2009542359A (en) | 2006-06-29 | 2009-12-03 | ボストン サイエンティフィック リミテッド | Medical device with selective covering |
US10219884B2 (en) | 2006-07-10 | 2019-03-05 | First Quality Hygienic, Inc. | Resilient device |
US8613698B2 (en) | 2006-07-10 | 2013-12-24 | Mcneil-Ppc, Inc. | Resilient device |
US10004584B2 (en) | 2006-07-10 | 2018-06-26 | First Quality Hygienic, Inc. | Resilient intravaginal device |
US8177706B2 (en) * | 2006-07-10 | 2012-05-15 | Mcneil-Ppc, Inc. | Method of treating urinary incontinence |
BRPI0714288B1 (en) * | 2006-07-10 | 2018-06-26 | Mcneil-Ppc, Inc. | INTRAVAGINAL URINARY INCONTINENCE DEVICE |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
GB0616729D0 (en) * | 2006-08-23 | 2006-10-04 | Angiomed Ag | Method of welding a component to a shape memory alloy workpiece |
GB0616999D0 (en) * | 2006-08-29 | 2006-10-04 | Angiomed Ag | Annular mesh |
EP2063824B1 (en) * | 2006-09-07 | 2020-10-28 | Angiomed GmbH & Co. Medizintechnik KG | Helical implant having different ends |
EP2068757B1 (en) | 2006-09-14 | 2011-05-11 | Boston Scientific Limited | Medical devices with drug-eluting coating |
EP2959925B1 (en) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medical devices and methods of making the same |
WO2008034048A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprosthesis with biostable inorganic layers |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
JP2010503489A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
JP2010503490A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adjustable surface features |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US7780798B2 (en) * | 2006-10-13 | 2010-08-24 | Boston Scientific Scimed, Inc. | Medical devices including hardened alloys |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
GB0622465D0 (en) | 2006-11-10 | 2006-12-20 | Angiomed Ag | Stent |
JP2010509988A (en) | 2006-11-16 | 2010-04-02 | ボストン サイエンティフィック リミテッド | Stents that release therapeutic agents to the outer and luminal sides at different times |
GB0624419D0 (en) * | 2006-12-06 | 2007-01-17 | Angiomed Ag | Stenting ring with marker |
EP2125066A2 (en) | 2006-12-20 | 2009-12-02 | Boston Scientific Limited | Stent with a coating for delivering a therapeutic agent |
ES2356274T3 (en) | 2006-12-28 | 2011-04-06 | Boston Scientific Limited | BIODEGRADABLE ENDOPROTESIS AND MANUFACTURING PROCEDURES OF THE SAME. |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
US20080166526A1 (en) * | 2007-01-08 | 2008-07-10 | Monk Russell A | Formed panel structure |
US7972375B2 (en) * | 2007-02-05 | 2011-07-05 | Boston Scientific Scimed, Inc. | Endoprostheses including metal matrix composite structures |
GB0703379D0 (en) * | 2007-02-21 | 2007-03-28 | Angiomed Ag | Stent with radiopaque marker |
US7458803B2 (en) * | 2007-02-27 | 2008-12-02 | Husky Injection Molding Systems Ltd. | Composite injection molding component |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
GB0706499D0 (en) * | 2007-04-03 | 2007-05-09 | Angiomed Ag | Bendable stent |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US8409270B2 (en) * | 2007-04-16 | 2013-04-02 | Boston Scientific Scimed, Inc. | Radiopaque compositions, stents and methods of preparation |
US8500787B2 (en) * | 2007-05-15 | 2013-08-06 | Abbott Laboratories | Radiopaque markers and medical devices comprising binary alloys of titanium |
US8500786B2 (en) * | 2007-05-15 | 2013-08-06 | Abbott Laboratories | Radiopaque markers comprising binary alloys of titanium |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
JP2010527746A (en) | 2007-05-25 | 2010-08-19 | ミセル テクノロジーズ、インコーポレイテッド | Polymer film for medical device coating |
US8398702B2 (en) * | 2007-06-29 | 2013-03-19 | Boston Scientific Scimed, Inc. | Molybdenum endoprostheses |
DE102007030751B4 (en) * | 2007-07-02 | 2009-06-10 | Acandis Gmbh & Co. Kg | Method of making a stent |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7604662B2 (en) * | 2007-07-13 | 2009-10-20 | Boston Scientific Scimed, Inc. | Endoprostheses containing boride intermetallic phases |
EP2187988B1 (en) | 2007-07-19 | 2013-08-21 | Boston Scientific Limited | Endoprosthesis having a non-fouling surface |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
JP2010535541A (en) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | Coating for medical devices with large surface area |
GB0717481D0 (en) | 2007-09-07 | 2007-10-17 | Angiomed Ag | Self-expansible stent with radiopaque markers |
US8221783B2 (en) | 2007-09-10 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
WO2009041359A1 (en) * | 2007-09-25 | 2009-04-02 | Kabushiki Kaisha Toshiba | Medical guidewire |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8118857B2 (en) * | 2007-11-29 | 2012-02-21 | Boston Scientific Corporation | Medical articles that stimulate endothelial cell migration |
US8623071B2 (en) * | 2008-01-07 | 2014-01-07 | DePuy Synthes Products, LLC | Radiopaque super-elastic intravascular stent |
WO2009099935A2 (en) * | 2008-02-01 | 2009-08-13 | Boston Scientific Scimed, Inc. | Drug-coated medical devices for differential drug release |
CN102083397B (en) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | Stents having bioabsorbable layers |
WO2009131911A2 (en) | 2008-04-22 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20090287301A1 (en) * | 2008-05-16 | 2009-11-19 | Boston Scientific, Scimed Inc. | Coating for medical implants |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2303350A2 (en) | 2008-06-18 | 2011-04-06 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
JP2010092330A (en) * | 2008-10-09 | 2010-04-22 | Seiko Epson Corp | Operation sequence creating apparatus, method for controlling the same, and program |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US8151682B2 (en) | 2009-01-26 | 2012-04-10 | Boston Scientific Scimed, Inc. | Atraumatic stent and method and apparatus for making the same |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
US20110152604A1 (en) * | 2009-12-23 | 2011-06-23 | Hull Jr Raymond J | Intravaginal incontinence device |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US8658006B2 (en) | 2010-04-12 | 2014-02-25 | Abbott Cardiovascular Systems Inc. | System and method for electropolising devices |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US9155643B2 (en) | 2010-04-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Apparatus and method for manufacturing a single wire stent |
WO2011136963A1 (en) | 2010-04-30 | 2011-11-03 | Boston Scientific Scimed, Inc. | Duodenal metabolic stent |
US9561308B2 (en) | 2010-06-25 | 2017-02-07 | Fort Wayne Metal Research Products Corporation | Biodegradable composite wire for medical devices |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
US11298251B2 (en) | 2010-11-17 | 2022-04-12 | Abbott Cardiovascular Systems, Inc. | Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content |
US9566147B2 (en) | 2010-11-17 | 2017-02-14 | Abbott Cardiovascular Systems, Inc. | Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof |
EP2648791A1 (en) | 2010-12-08 | 2013-10-16 | Boston Scientific Scimed, Inc. | Drug eluting balloons with ability for double treatment |
US20120221084A1 (en) | 2011-02-28 | 2012-08-30 | Medtronic, Inc. | Medical Electrical Lead |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US9724494B2 (en) | 2011-06-29 | 2017-08-08 | Abbott Cardiovascular Systems, Inc. | Guide wire device including a solderable linear elastic nickel-titanium distal end section and methods of preparation therefor |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US9119736B2 (en) * | 2012-01-27 | 2015-09-01 | Medtronic Vascular, Inc. | Hollow drug-filled stent and method of forming hollow drug-filled stent |
WO2013152327A1 (en) * | 2012-04-06 | 2013-10-10 | Merlin Md Pte Ltd. | Devices and methods for treating an aneurysm |
US9339398B2 (en) * | 2012-04-26 | 2016-05-17 | Medtronic Vascular, Inc. | Radiopaque enhanced nickel alloy for stents |
EP2967803B1 (en) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US9545301B2 (en) | 2013-03-15 | 2017-01-17 | Covidien Lp | Coated medical devices and methods of making and using same |
US9320592B2 (en) | 2013-03-15 | 2016-04-26 | Covidien Lp | Coated medical devices and methods of making and using same |
EP2989225B1 (en) | 2013-04-26 | 2021-07-07 | Icon Medical Corp. | Improved metal alloys for medical devices |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
WO2015054101A1 (en) | 2013-10-09 | 2015-04-16 | Icon Medical Corp. | Improved metal alloy for medical devices |
EP4147680A1 (en) | 2013-11-08 | 2023-03-15 | Boston Scientific Scimed, Inc. | Endoluminal device |
US9668890B2 (en) | 2013-11-22 | 2017-06-06 | Covidien Lp | Anti-thrombogenic medical devices and methods |
CN106535826A (en) | 2014-06-24 | 2017-03-22 | 怡康医疗股份有限公司 | Improved metal alloys for medical devices |
US9789228B2 (en) | 2014-12-11 | 2017-10-17 | Covidien Lp | Antimicrobial coatings for medical devices and processes for preparing such coatings |
WO2017151548A1 (en) | 2016-03-04 | 2017-09-08 | Mirus Llc | Stent device for spinal fusion |
GB201804408D0 (en) | 2018-03-20 | 2018-05-02 | Smiths Medical International Ltd | Tracheal tubes |
US11547835B2 (en) | 2018-09-17 | 2023-01-10 | Seigla Medical, Inc. | Systems, methods and apparatus for guiding and supporting catheters and methods of manufacture |
US11660420B2 (en) * | 2018-09-17 | 2023-05-30 | Seigla Medical, Inc. | Catheters and related devices and methods of manufacture |
GB202005470D0 (en) | 2020-04-15 | 2020-05-27 | Smiths Medical International Ltd | Reinforced medico-surgical tubes and their manufacture |
GB202006151D0 (en) | 2020-04-27 | 2020-06-10 | Smiths Medical International Ltd | Reinforced medico-surgical tubes anbd their manufacture |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE67929C (en) * | H. SPERL in Amberg, Oberpfalz | Rotary bodies suitable for knocking down cones and describing a spiral line when rolling | ||
US2524661A (en) * | 1947-05-03 | 1950-10-03 | Elgin Nat Watch Co | Alloy having high elastic strengths |
US3466166A (en) * | 1967-01-03 | 1969-09-09 | Gen Electric | Method for making a hollow metal article |
US3562024A (en) * | 1967-12-04 | 1971-02-09 | Standard Pressed Steel Co | Cobalt-nickel base alloys containing chromium and molybdenum |
US4023557A (en) * | 1975-11-05 | 1977-05-17 | Uop Inc. | Solar collector utilizing copper lined aluminum tubing and method of making such tubing |
US4281419A (en) * | 1979-12-10 | 1981-08-04 | Richards Manufacturing Company, Inc. | Middle ear ossicular replacement prosthesis having a movable joint |
US4465481A (en) * | 1981-02-26 | 1984-08-14 | Innovative Surgical Products, Inc. | Single piece wound drain catheter |
CH651463A5 (en) * | 1981-06-24 | 1985-09-30 | Sulzer Ag | STRING AND / OR TAPE REPLACEMENT. |
US4553545A (en) * | 1981-09-16 | 1985-11-19 | Medinvent S.A. | Device for application in blood vessels or other difficultly accessible locations and its use |
SE445884B (en) * | 1982-04-30 | 1986-07-28 | Medinvent Sa | DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION |
US4719916A (en) * | 1983-10-03 | 1988-01-19 | Biagio Ravo | Intraintestinal bypass tube |
JPS6082648A (en) * | 1983-10-08 | 1985-05-10 | Agency Of Ind Science & Technol | Process for forming material having high strength and difficult processability |
US4848348A (en) * | 1983-11-14 | 1989-07-18 | Minnesota Mining And Manufacturing Company | Coated films |
IT1186142B (en) * | 1984-12-05 | 1987-11-18 | Medinvent Sa | TRANSLUMINAL IMPLANTATION DEVICE |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4830262A (en) * | 1985-11-19 | 1989-05-16 | Nippon Seisen Co., Ltd. | Method of making titanium-nickel alloys by consolidation of compound material |
US4681110A (en) * | 1985-12-02 | 1987-07-21 | Wiktor Dominik M | Catheter arrangement having a blood vessel liner, and method of using it |
EP0556940A1 (en) * | 1986-02-24 | 1993-08-25 | Robert E. Fischell | Intravascular stent |
US4731084A (en) * | 1986-03-14 | 1988-03-15 | Richards Medical Company | Prosthetic ligament |
SE453258B (en) * | 1986-04-21 | 1988-01-25 | Medinvent Sa | ELASTIC, SELF-EXPANDING PROTEST AND PROCEDURE FOR ITS MANUFACTURING |
US4819618A (en) * | 1986-08-18 | 1989-04-11 | Liprie Sam F | Iridium/platinum implant, method of encapsulation, and method of implantation |
US5024232A (en) * | 1986-10-07 | 1991-06-18 | The Research Foundation Of State University Of Ny | Novel radiopaque heavy metal polymer complexes, compositions of matter and articles prepared therefrom |
SE455834B (en) * | 1986-10-31 | 1988-08-15 | Medinvent Sa | DEVICE FOR TRANSLUMINAL IMPLANTATION OF A PRINCIPLE RODFORMALLY RADIALLY EXPANDABLE PROSTHESIS |
IT1202558B (en) * | 1987-02-17 | 1989-02-09 | Alberto Arpesani | INTERNAL PROSTHESIS FOR THE REPLACEMENT OF A PART OF THE HUMAN BODY PARTICULARLY IN THE VASCULAR OPERATIONS |
AU614092B2 (en) * | 1987-09-11 | 1991-08-22 | Paul Max Grinwald | Improved method and apparatus for enhanced drug permeation of skin |
AU623100B2 (en) * | 1987-10-08 | 1992-05-07 | Terumo Kabushiki Kaisha | Instrument and apparatus for securing inner diameter of lumen of tubular organ |
US4886062A (en) * | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5256764A (en) * | 1987-12-17 | 1993-10-26 | United States Surgical Corporation | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units |
JPH01259541A (en) * | 1988-04-11 | 1989-10-17 | Kobe Steel Ltd | Manufacture of compound bonding wire |
US4883486A (en) * | 1988-05-31 | 1989-11-28 | Indu Kapadia | Prosthetic ligament |
US4830003A (en) * | 1988-06-17 | 1989-05-16 | Wolff Rodney G | Compressive stent and delivery system |
US5374261A (en) * | 1990-07-24 | 1994-12-20 | Yoon; Inbae | Multifunctional devices for use in endoscopic surgical procedures and methods-therefor |
US4980964A (en) * | 1988-08-19 | 1991-01-01 | Jan Boeke | Superconducting wire |
US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
SE8803444D0 (en) * | 1988-09-28 | 1988-09-28 | Medinvent Sa | A DEVICE FOR TRANSLUMINAL IMPLANTATION OR EXTRACTION |
US5207706A (en) * | 1988-10-05 | 1993-05-04 | Menaker M D Gerald | Method and means for gold-coating implantable intravascular devices |
US5019085A (en) * | 1988-10-25 | 1991-05-28 | Cordis Corporation | Apparatus and method for placement of a stent within a subject vessel |
US5001825A (en) * | 1988-11-03 | 1991-03-26 | Cordis Corporation | Catheter guidewire fabrication method |
US4950227A (en) * | 1988-11-07 | 1990-08-21 | Boston Scientific Corporation | Stent delivery system |
EP0395098B1 (en) * | 1989-04-28 | 1994-04-06 | Tokin Corporation | Readily operable catheter guide wire using shape memory alloy with pseudo elasticity |
US5003989A (en) * | 1989-05-11 | 1991-04-02 | Advanced Cardiovascular Systems, Inc. | Steerable dilation catheter |
US5015253A (en) * | 1989-06-15 | 1991-05-14 | Cordis Corporation | Non-woven endoprosthesis |
CA2026604A1 (en) * | 1989-10-02 | 1991-04-03 | Rodney G. Wolff | Articulated stent |
US5176617A (en) * | 1989-12-11 | 1993-01-05 | Medical Innovative Technologies R & D Limited Partnership | Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct |
US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5071407A (en) * | 1990-04-12 | 1991-12-10 | Schneider (U.S.A.) Inc. | Radially expandable fixation member |
US5203348A (en) * | 1990-06-06 | 1993-04-20 | Cardiac Pacemakers, Inc. | Subcutaneous defibrillation electrodes |
US5064435A (en) * | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
US5139480A (en) * | 1990-08-22 | 1992-08-18 | Biotech Laboratories, Inc. | Necking stents |
US5217483A (en) * | 1990-11-28 | 1993-06-08 | Numed, Inc. | Intravascular radially expandable stent |
US5984877A (en) * | 1991-02-05 | 1999-11-16 | Fleischhacker, Jr.; Joseph F. | Guide wire marker technique and coil spring marker technique |
US5213111A (en) * | 1991-07-10 | 1993-05-25 | Cook Incorporated | Composite wire guide construction |
US5320100A (en) * | 1991-09-16 | 1994-06-14 | Atrium Medical Corporation | Implantable prosthetic device having integral patency diagnostic indicia |
GB2260287A (en) * | 1991-10-10 | 1993-04-14 | Micropore International Ltd | Drawing insulated tube |
CA2079417C (en) * | 1991-10-28 | 2003-01-07 | Lilip Lau | Expandable stents and method of making same |
WO1993019803A1 (en) * | 1992-03-31 | 1993-10-14 | Boston Scientific Corporation | Medical wire |
US5382259A (en) * | 1992-10-26 | 1995-01-17 | Target Therapeutics, Inc. | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
US5389106A (en) * | 1993-10-29 | 1995-02-14 | Numed, Inc. | Impermeable expandable intravascular stent |
-
1993
- 1993-11-23 WO PCT/US1993/011262 patent/WO1994016646A1/en active IP Right Grant
- 1993-11-23 KR KR1019950702932A patent/KR0147482B1/en active
- 1993-11-23 EP EP94902318A patent/EP0773751B1/en not_active Expired - Lifetime
- 1993-11-23 AU AU56726/94A patent/AU673878B2/en not_active Ceased
- 1993-11-23 KR KR1019950702932A patent/KR960700025A/en not_active IP Right Cessation
- 1993-11-23 BR BR9307814A patent/BR9307814A/en not_active Application Discontinuation
- 1993-11-23 CA CA002152594A patent/CA2152594C/en not_active Expired - Fee Related
- 1993-11-23 ES ES94902318T patent/ES2166370T3/en not_active Expired - Lifetime
- 1993-11-23 AT AT94902318T patent/ATE207728T1/en not_active IP Right Cessation
- 1993-11-23 DE DE69331069T patent/DE69331069T2/en not_active Expired - Lifetime
- 1993-11-23 JP JP6516995A patent/JP2746755B2/en not_active Expired - Fee Related
- 1993-11-26 TW TW082109981A patent/TW234689B/zh active
-
1994
- 1994-01-13 IL IL10832594A patent/IL108325A/en not_active IP Right Cessation
- 1994-01-18 ZA ZA94334A patent/ZA94334B/en unknown
-
1995
- 1995-06-06 US US08/469,810 patent/US5824077A/en not_active Expired - Lifetime
- 1995-06-07 US US08/485,626 patent/US5800511A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,121 patent/US5628787A/en not_active Expired - Lifetime
- 1995-07-18 FI FI953472A patent/FI953472A0/en unknown
- 1995-07-18 NO NO952852A patent/NO952852L/en unknown
-
1996
- 1996-12-12 US US08/764,130 patent/US5679470A/en not_active Expired - Lifetime
-
1997
- 1997-02-28 AU AU15014/97A patent/AU689739B2/en not_active Ceased
-
1998
- 1998-12-07 IL IL12741898A patent/IL127418A0/en unknown
-
2002
- 2002-06-19 US US10/175,254 patent/US20030009215A1/en not_active Abandoned
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925074B2 (en) | 1999-02-01 | 2018-03-27 | Board Of Regents, The University Of Texas System | Plain woven stents |
US8974516B2 (en) | 1999-02-01 | 2015-03-10 | Board Of Regents, The University Of Texas System | Plain woven stents |
US8876880B2 (en) | 1999-02-01 | 2014-11-04 | Board Of Regents, The University Of Texas System | Plain woven stents |
US8414635B2 (en) | 1999-02-01 | 2013-04-09 | Idev Technologies, Inc. | Plain woven stents |
US20060089568A1 (en) * | 2001-01-12 | 2006-04-27 | Mx Medical, Inc. | Titanium molybdenum alloy guidewire |
US7468045B2 (en) * | 2001-01-12 | 2008-12-23 | Minnesota Medical Development, Inc. | Titanium molybdenum alloy guidewire |
US20040048825A1 (en) * | 2001-10-10 | 2004-03-11 | Monia Brett P. | Antisense modulation of CREB expression |
US20040236433A1 (en) * | 2003-05-23 | 2004-11-25 | Kennedy Richard L. | Cobalt alloys, methods of making cobalt alloys, and implants and articles of manufacture made therefrom |
US7520947B2 (en) | 2003-05-23 | 2009-04-21 | Ati Properties, Inc. | Cobalt alloys, methods of making cobalt alloys, and implants and articles of manufacture made therefrom |
US8333798B2 (en) * | 2003-11-07 | 2012-12-18 | Merlin Md Pte Ltd. | Implantable medical devices with enhanced visibility, mechanical properties and biocompatability |
US20070067009A1 (en) * | 2003-11-07 | 2007-03-22 | Deepak Gandhi | Implantable medical devices with enhanced visibility, mechanical properties and biocompatability |
US9855047B2 (en) | 2004-05-25 | 2018-01-02 | Covidien Lp | Flexible vascular occluding device |
US10765542B2 (en) | 2004-05-25 | 2020-09-08 | Covidien Lp | Methods and apparatus for luminal stenting |
US10004618B2 (en) | 2004-05-25 | 2018-06-26 | Covidien Lp | Methods and apparatus for luminal stenting |
US9801744B2 (en) | 2004-05-25 | 2017-10-31 | Covidien Lp | Methods and apparatus for luminal stenting |
US9393021B2 (en) | 2004-05-25 | 2016-07-19 | Covidien Lp | Flexible vascular occluding device |
US10918389B2 (en) | 2004-05-25 | 2021-02-16 | Covidien Lp | Flexible vascular occluding device |
US20140018843A1 (en) * | 2004-05-25 | 2014-01-16 | Covidien Lp | Methods and apparatus for luminal stenting |
US9295568B2 (en) * | 2004-05-25 | 2016-03-29 | Covidien Lp | Methods and apparatus for luminal stenting |
US11771433B2 (en) | 2004-05-25 | 2023-10-03 | Covidien Lp | Flexible vascular occluding device |
US9125659B2 (en) | 2004-05-25 | 2015-09-08 | Covidien Lp | Flexible vascular occluding device |
US12042411B2 (en) | 2004-05-25 | 2024-07-23 | Covidien Lp | Methods and apparatus for luminal stenting |
US9050205B2 (en) | 2004-05-25 | 2015-06-09 | Covidien Lp | Methods and apparatus for luminal stenting |
EP1655384A1 (en) * | 2004-11-09 | 2006-05-10 | Cordis Corporation | A cobalt-chromium-molybdenum fatigue resistant alloy for intravascular medical devices |
US20060100692A1 (en) * | 2004-11-09 | 2006-05-11 | Robert Burgermeister | Cobalt-chromium-molybdenum fatigue resistant alloy for intravascular medical devices |
US20060153729A1 (en) * | 2005-01-13 | 2006-07-13 | Stinson Jonathan S | Medical devices and methods of making the same |
US7727273B2 (en) | 2005-01-13 | 2010-06-01 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US7938854B2 (en) | 2005-01-13 | 2011-05-10 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US20100228336A1 (en) * | 2005-01-13 | 2010-09-09 | Stinson Jonathan S | Medical devices and methods of making the same |
US20110060400A1 (en) * | 2005-03-14 | 2011-03-10 | Abbott Laboratories | Visible endoprosthesis |
US10433988B2 (en) | 2006-02-22 | 2019-10-08 | Covidien Lp | Stents having radiopaque mesh |
US11382777B2 (en) | 2006-02-22 | 2022-07-12 | Covidien Lp | Stents having radiopaque mesh |
US9320590B2 (en) | 2006-02-22 | 2016-04-26 | Covidien Lp | Stents having radiopaque mesh |
US9610181B2 (en) | 2006-02-22 | 2017-04-04 | Covidien Lp | Stents having radiopaque mesh |
US8876881B2 (en) | 2006-10-22 | 2014-11-04 | Idev Technologies, Inc. | Devices for stent advancement |
US9408730B2 (en) | 2006-10-22 | 2016-08-09 | Idev Technologies, Inc. | Secured strand end devices |
US9408729B2 (en) | 2006-10-22 | 2016-08-09 | Idev Technologies, Inc. | Secured strand end devices |
US10470902B2 (en) | 2006-10-22 | 2019-11-12 | Idev Technologies, Inc. | Secured strand end devices |
US9585776B2 (en) | 2006-10-22 | 2017-03-07 | Idev Technologies, Inc. | Secured strand end devices |
US8419788B2 (en) | 2006-10-22 | 2013-04-16 | Idev Technologies, Inc. | Secured strand end devices |
US9629736B2 (en) | 2006-10-22 | 2017-04-25 | Idev Technologies, Inc. | Secured strand end devices |
US8739382B2 (en) | 2006-10-22 | 2014-06-03 | Idev Technologies, Inc. | Secured strand end devices |
US9149374B2 (en) | 2006-10-22 | 2015-10-06 | Idev Technologies, Inc. | Methods for manufacturing secured strand end devices |
US9895242B2 (en) | 2006-10-22 | 2018-02-20 | Idev Technologies, Inc. | Secured strand end devices |
US8966733B2 (en) | 2006-10-22 | 2015-03-03 | Idev Technologies, Inc. | Secured strand end devices |
US20120239157A1 (en) * | 2007-08-20 | 2012-09-20 | Depuy Products, Inc. | Ultra-passivation of chromium containing alloy and methods of producing same |
US9023095B2 (en) | 2010-05-27 | 2015-05-05 | Idev Technologies, Inc. | Stent delivery system with pusher assembly |
US9907643B2 (en) | 2012-10-30 | 2018-03-06 | Covidien Lp | Systems for attaining a predetermined porosity of a vascular device |
US9301831B2 (en) | 2012-10-30 | 2016-04-05 | Covidien Lp | Methods for attaining a predetermined porosity of a vascular device |
US9114001B2 (en) | 2012-10-30 | 2015-08-25 | Covidien Lp | Systems for attaining a predetermined porosity of a vascular device |
US10206798B2 (en) | 2012-10-31 | 2019-02-19 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US10952878B2 (en) | 2012-10-31 | 2021-03-23 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9943427B2 (en) | 2012-11-06 | 2018-04-17 | Covidien Lp | Shaped occluding devices and methods of using the same |
US9561122B2 (en) | 2013-02-05 | 2017-02-07 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9157174B2 (en) | 2013-02-05 | 2015-10-13 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9918856B2 (en) * | 2013-06-21 | 2018-03-20 | Universite Grenoble Alpes | Stent spacer |
US20160151179A1 (en) * | 2013-06-21 | 2016-06-02 | Universite Joseph Fourier | Stent spacer |
WO2022002281A1 (en) * | 2020-06-30 | 2022-01-06 | 微创神通医疗科技(上海)有限公司 | Vascular stent |
Also Published As
Publication number | Publication date |
---|---|
BR9307814A (en) | 1995-11-14 |
FI953472A (en) | 1995-07-18 |
ATE207728T1 (en) | 2001-11-15 |
US5679470A (en) | 1997-10-21 |
FI953472A0 (en) | 1995-07-18 |
CA2152594A1 (en) | 1994-08-04 |
IL127418A0 (en) | 1999-10-28 |
US5824077A (en) | 1998-10-20 |
JP2746755B2 (en) | 1998-05-06 |
NO952852D0 (en) | 1995-07-18 |
AU5672694A (en) | 1994-08-15 |
KR960700025A (en) | 1996-01-19 |
EP0773751A1 (en) | 1997-05-21 |
KR0147482B1 (en) | 1998-08-01 |
ES2166370T3 (en) | 2002-04-16 |
TW234689B (en) | 1994-11-21 |
AU673878B2 (en) | 1996-11-28 |
IL108325A (en) | 2000-02-17 |
US5628787A (en) | 1997-05-13 |
US5800511A (en) | 1998-09-01 |
WO1994016646A1 (en) | 1994-08-04 |
NO952852L (en) | 1995-07-18 |
IL108325A0 (en) | 1994-04-12 |
ZA94334B (en) | 1995-07-18 |
DE69331069D1 (en) | 2001-12-06 |
CA2152594C (en) | 1998-12-01 |
AU689739B2 (en) | 1998-04-02 |
JPH08502436A (en) | 1996-03-19 |
DE69331069T2 (en) | 2002-07-04 |
EP0773751B1 (en) | 2001-10-31 |
AU1501497A (en) | 1997-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6527802B1 (en) | Clad composite stent | |
CA2188429C (en) | Clad composite stent | |
US20030009215A1 (en) | Clad composite stent | |
US20090276033A1 (en) | Clad Composite Stent | |
US6248190B1 (en) | Process of making composite stents with gold alloy cores | |
US6290721B1 (en) | Tubular medical endoprostheses | |
US7101392B2 (en) | Tubular medical endoprostheses | |
JP4652375B2 (en) | Endoprosthesis | |
JPH11319070A (en) | Endoprosthesis | |
MXPA96005485A (en) | Compound implant recubie | |
MX9605485A (en) | Clad composite stent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |